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ABSTRACT 
Background: Immune response during HIV-1 infection and replication is quite 
complex because many viral and host factors, beyond individual variables, are 
involved at different levels. Many efforts have been made to evaluate the influence 
of these factors on HIV-1 infection and disease progression mainly focusing on the 
identification of genetic variants that can play a role in HIV-1 infection susceptibility. 
These studies have led to the concept of "immunological advantage". Moreover, the 
immunological advantage characterizing natural resistance to HIV-1 in HESN (HIV-
exposed seronegative) has been associated with a number of polymorphisms 
(SNPs) in immune genes (e.g. ERAP2, APOBEC3H, MX2 and TLR3). However, the 
role of these SNPs in response to combination antiretroviral therapy (cART) has 
never been investigated. Among “protective” genes mentioned above, Endoplasmic 
Reticulum Aminopeptidase 2 (ERAP2) is involved in antigen presentation, trimming 
the amino-terminus of peptide precursors to the correct size for binding to HLA class 
I molecules. Haplotype-specific alternative splicing of the ERAP2 gene results in 
either a spliced (Hap B) or full-length (Hap A) mRNA. Interestingly, the frequency of 
the latter is higher in HESNs individuals and Hap A results correlated to in vitro HIV-
1 infection natural resistance. Finally, the possibility of an alternative ERAP2 cellular 
localization has been recently investigated.  
The project aims to: 1) deepen the correlation between ERAP2 haplotypes and in 
vitro HIV-1 susceptibility; 2) investigate the role played by ERAP2 genetic variants 
and progression of HIV-1 infection in cART treated patients; and 3) examine the 
molecular mechanism by which Hap A and Hap B control peptide production for 
antigen presentation and the resulting CD8 mediated immune response.  
Methodology: To investigate the role of “protective” SNPs in response to cART, 300 
HIV-1-infected patients from the Italian ICONA cohort undergoing a first HAART 
regimen were enrolled and genotyped for the “resistance” variants in ERAP2, TLR3, 
APOBEC3H and MX2 genes. Periodically (basal, 6 months and 1 year post cART 
initiation) HIV-infected patients’ clinical parameters (gender, CD4/CD8 cell count, 
viral load, therapies, year of infection, clinical evolution) were collected and analysed 
for possible correlation with the above mentioned genetic variants.  
In parallel, to investigate the role of ERAP2 in in vitro HIV-1 susceptibility, PBMCs 
isolated from 30 healthy control (HC), grouped according to their ERAP2 genotype, 
were infected with HIV-1Ba-L in presence/absence of recombinant (rh) ERAP2 
(100ng/mL) or with/without DG013A (100 nM/mL), an ERAP2 inhibitor, and analysed 
for: 1) susceptibility to HIV-1 infection (p24 ELISA assay); 2) expression mRNA 
levels of genes involved in the antigen presentation pathway; 3) MHC class I 
expression in cells and cytotoxic response by  perforin/granzyme expression on 
CD8+ T cells.  In addition, the trimming ability and modulation of CD8+ T cell 
response of Hap A and Hap B ERAP2 were assessed following transfection of DNA 
model constructs into ERAP2 deficient cells expressing a peptide precursor and 
evaluating by CPRG assay and B3Z response.  
 
Findings: Results obtained from HIV-1-infected patients undergoing cART therapy 
did not show any significant correlations between the genotypes of TLR3, 
APOBEC3G and MX2 (single or combined) and the progression of HIV-1 infection. 
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The only exception was represented by ERAP2 gene, where HIV-infected Caucasian 
patients with a GG homozygosis condition for rs2549782 SNP (Hap A) showed a 
significant reduction (p=0.042) in viral load and a recovery in CD4+ T cells compared 
to heterozygous or homozygous TT patients (Hap B). Data obtained in Hap A HC 
showed a less susceptibility to in vitro HIV-1 infection compared to Hap B. Inhibition 
of ERAP2 activity by DG013A peptide increased HIV-1 infection in all PBMCs 
independently from their haplotypes. The role of ERAP2 in antigen processing in 
HIV-1 susceptibility has been confirmed by increased mRNA expression of other 
aminopeptidases and transporter, such as ERAP1 and TAP1 (P<0.05; 
P<0.01;P<0.005), in a condition where ERAP2 was inhibited. In line with these 
findings, transfection experiments showed that models for Hap A ERAP2 trimmed 
the peptide precursor efficiently, whereas Hap B ERAP2 constructs showed a 
reduction in trimming activity which resulted in a decreased  CD8+ T cell response 
(P<0.05, P<0.005, P<0.001). 
Addition of rhERAP2 to in vitro HIV-infected cells coupled with a reduction of viral 
replication in both ERAP2 haplotypes (p<0.01), without affecting cell viability.  This 
protective effect was independent from an increase of HLA-ABC expression and/or 
of perforin and granzymes expression by CD8+ T lymphocytes.  
 
Conclusions: Haplotype A of ERAP2 is associated with a reduced in vitro HIV-1 
susceptibility as well as slower disease progression in cART treated HIV-1 infected 
patients. The effect may be explained by a greater control of antigen presentation 
pathway in Hap A subjects, in terms of trimming activity and consequently 
modulation of CD8+ T cell immune response. The role of ERAP2 in the extracellular 
milieu is still undisclosed and needs further investigation. However, data herein 
suggest a defensive feature mediated through an unconventional mechanism, 
distinct from immune system modulation. 
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SOMMARIO 
Introduzione: La risposta immunitaria contro HIV è composita e complessa: entrano 
in gioco molti fattori appartenenti sia al virus che all’ospite e le variabili interindividuali 
non sono trascurabili e agiscono su vari livelli. Molti studi sono stati condotti per 
valutare l’influenza che questi diversi fattori possono esercitare sull’infezione da HIV-
1 e sulla progressione della malattia e particolare interesse è stato rivolto 
all’identificazione di fattori genetici in grado di modulare la suscettibilità all’infezione 
da HIV. Questo orientamento ha portato alla elaborazione del concetto di “vantaggio 
immunologico” che sembra contraddistinguere la naturale resistenza ad HIV 
riscontrata in individui HIV-esposti sieronegativi (HESN). In particolare, in questi 
soggetti tale resistenza è stata correlata a diversi polimorfismi genetici (SNPs) in 
geni che esercitano un ruolo nell’organizzazione e funzionamento del sistema 
immunitario (es. ERAP2, APOBEC3H, MX2 e TLR3). Tuttavia, l’eventuale 
coinvolgimento di questi SNP in pazienti sieropositivi sottoposti ad una terapia 
antiretrovirale combinata (cART) non è mai stato investigato. Tra i geni “protettivi” 
menzionati sopra, Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) è un enzima 
coinvolto nel processo di presentazione antigenica, infatti, taglia le estremità amino 
terminali di precursori peptidici adattandoli alla corretta lunghezza per il legame con 
la tasca delle molecole HLA di classe I. Splicing alternativi aplotipo-specifici sul gene 
di ERAP2 originano sia un trascritto alternativo (Hap B) sia un trascritto definito full-
lenght (Hap A). E’ Interessante osservare che la frequenza di quest’ultimo risulta 
maggiore in individui HESN e, inoltre, la presenza dell’aplotipo A è stata correlata 
alla naturale resistenza all’ infezione da HIV in vitro. Infine, recentemente, è stata 
discussa la possibilità dell’esistenza di una localizzazione di ERAP2 alternativa da 
quella consueta a livello del reticolo endoplasmatico. 
Alla luce di queste osservazioni il progetto di ricerca si propone di: 1) approfondire 
la correlazione tra aplotipi di ERAP2 e la suscettibilità in vitro al virus dell’HIV-1; 2) 
investigare il ruolo di varianti genetiche associate ad ERAP2 in rapporto alla 
progressione dell’infezione virale in pazienti sieropositivi riceventi terapia cART; ed 
3) esaminare il meccanismo molecolare attraverso il quale Hap A e Hap B mediano 
la produzione di peptidi destinati alla presentazione antigenica e, di conseguenza, 
la risultante risposta immunitaria mediata da linfociti T CD8+.  
Metodi: Per investigare il ruolo svolto da SNP definiti “protettivi” in risposta alla cART 
sono stati arruolati 300 pazienti provenienti dalla corte italiana ICONA, riceventi per 
la prima volta la terapia HAART, sui quali sono state condotte analisi per 
genotipizzare le varianti resistenti sui geni codificanti ERAP2, TLR3, APOBEC3H e 
MX2. Periodicamente (basale, 6 mesi ed 1 anno dall’inizio della terapia cART) sono 
stati raccolti i parametri clinici dei pazienti (genere, conta cellulare CD4/CD8, carica 
virale (VL), terapia, anno di infezione, evoluzione clinica) e, successivamente, 
analizzati per identificare una possibile correlazione con le varianti genetiche citate 
in precedenza. 
In parallelo, per approfondire il ruolo rivestito da ERAP2 nella suscettibilità in vitro a 
HIV-1, PBMCs, isolate da 30 donatori sani (HC) suddivisi in funzione del loro 
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genotipo per ERAP2, sono state infettate in vitro con HIV-1Ba-L in presenza/assenza 
di ERAP2 ricombinante (rh) (100ng/mL) o in presenza/assenza di DG013A (100 
nM/mL), un inibitore di ERAP2. In seguito le culture cellulari sono state analizzate 
per valutare: 1) la suscettibilità all’ infezione da HIV-1 (saggio ELISA); 2) 
l’espressione dei livelli dei trascritti (mRNA) di geni coinvolti nei meccanismi di 
presentazione antigenica; 3) l’espressione di molecole MHC di classe I  e la 
valutazione della risposta citotossica attraverso misurazione dei livelli di 
perforina/granzimi su cellule CD8+. Inoltre, l’abilità di taglio e la modulazione della 
risposta cellulare CD8-mediata di Hap A e Hap B è stata valutata attraverso saggi di 
trasfezione con costrutti modello su cellule ERAP2 deficienti, esprimenti precursori 
peptidici e valutati attraverso saggio CPRG e risposta B3Z.  
 
Risultati: I risultati ottenuti da pazienti HIV-1 infetti sottoposti a terapia cART non 
hanno mostrato nessuna correlazione significativa tra i genotipi di TLR3, 
APOBEC3G and MX2 (singoli o combinati) e la progressione dell’infezione da HIV-
1. L’unica eccezione è rappresentata dal gene ERAP2, dove pazienti HIV-1 infetti di 
origine caucasica con condizione di omozigosi GG per rs2549782 SNP (Hap A) 
hanno mostrato una significativa riduzione (p=0.042) in carica virale e ripristino dei 
valori cellulari di linfociti CD4+, comparati ai pazienti eterozigoti o TT omozigoti (Hap 
B). I dati ottenuti da Hap A HC hanno mostrato una minor suscettibilità ad 
un’infezione in vitro rispetto a Hap B. L’inibizione dell’attività di ERAP2, ad opera del 
peptide DG013A, ha portato ad un aumento dell’infezione da HIV-1 in tutte le 
PBMCs, indipendentemente dal relativo aplotipo. Il ruolo mediato da ERAP2 nel 
processamento antigenico correlato alla suscettibilità verso HIV-1 è stato 
confermato da un aumento dell’espressione di trascritti (mRNA) di altre 
aminopeptidasi e trasportatori specifici, come ad esempio ERAP1 e TAP1 (P<0.05; 
P<0.01;P<0.005), in condizioni nelle quali ERAP2 era inibito. In linea con questi dati, 
esperimenti di trasfezione hanno mostrato che i modelli per ERAP2 Hap A 
presentano un’attività di processamento peptidico più efficiente, mentre costrutti 
modello per ERAP2 Hap B hanno mostrato una ridotta attività di taglio risultante in 
una diminuzione della risposta cellulare CD8-mediata (P<0.05, P<0.005, P<0.001). 
L’aggiunta in vitro di rhERAP2 in cellule infettate con HIV ha portato ad una riduzione 
della replicazione virale in entrambi gli aplotipi di ERAP2 (p<0.01), senza influenzare 
però la vitalità cellulare. Questo effetto protettivo è stato raggiunto indipendente 
dall’aumento dell’espressione di molecole HLA-ABC e/o innalzamento dei livelli di 
perforina e granzimi sui linfociti CD8+.  
 
Conclusioni: L’aplotipo A di ERAP2 è associato sia ad una riduzione della 
suscettibilità a HIV-1 in vitro sia ad una progressione più lenta della malattia in 
pazienti HIV-1 infetti sottoposti a trattamento cART. L’effetto può essere giustificato 
da un miglior controllo del meccanismo di presentazione antigenica in soggetti Hap 
A, definita in termini di attività di processamento peptidico e conseguente 
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modulazione della risposta immune T CD8 mediata. Il ruolo extracellulare di ERAP2 
è ancora in discussione e richiede ulteriori indagini. Nonostante ciò, i dati ottenuti 
suggeriscono un ruolo protettivo mediato da ERAP2 nell’infezione da HIV-1, 
probabilmente esercitato attraverso meccanismi non convenzionali, indipendenti 
dalla modulazione del sistema immunitario. 
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dsDNA: double stranded DNA 
dsRNA: stranded RNA 
EC: endothelial cells  
ER: endoplasmic reticulum 
ERAAP: ER aminopeptidase associate with antigen processing  
ERAP1: Endoplasmic Reticulum Associated Aminopepetidase type 1 
ERAP2: Endoplasmic Reticulum Associated Aminopepetidase type 2 
ERAP2-AS: alternatively spliced ERAP2 
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ESN: exposed seronegatives 
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Hap A: haplotype A ERAP2 (GG) 
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HCMV: human cytomegalo virus  
HIV: Human Immunodeficiency Virus 
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 X 
 
NIH: National Institute of Health 
NK: natural killer 
NMD: non-sense-mediated decay  
NNRTIs: Non-nucleoside reverse transcriptase inhibitors  
NRTIs: Nucleotide reverse transcriptase inhibitors  
OPD: ortho- phenylenediamine-HCl  
PAMPs: pathogen-associated molecular patterns  
PBMCs: Peripheral Blood Mononuclear Cells  
PBS: phosphate buffered saline  
PD-1: programmed death 1 factor 
PDI: Protein disulfide isomerase 
PDK1: phosphatidylinositol-dependent kinase 1  
PIC: pre-integration complex  
PILS-AP: puromycininsensitive leucine-specific aminopeptidase  
PIs: Protease inhibitors 
P-LAP: placental leucine aminopeptidase  
PLC: peptide loading complex 
pMHC: peptide bound to MHC molecules complex 
Pol: polymerase 
PPR: pattern recognition receptors 
PR: Protease 
PrEP: Pre-Exposure Prophylaxis 
PTC: papillary thyroid carcinoma  
RT: Reverse Transcriptase 
 XI 
 
SDM: site directed mutagenesis  
SHCS: Swiss HIV Cohort Study  
SIVs: simian immunodeficiency viruses 
SNP: single-nucleotide polymorphism 
SNPs: Single Nucleotide Polymorphisms  
ss: single stranded  
ssDNA: single-stranded DNA  
ssRNA: single-stranded RNA  
SV5: simian virus 5  
TAP: transporter associated with antigen processing 
TCR: T cell receptor 
Th: T helper CD4+ T 
TIM: T cell immunoglobulin domain and mucim domain 
TLR: Toll-Like Receptors  
TNF: tumor necrosis factor 
TNFR1: type I TNF receptor 
TPPII: tripeptidyl peptidase II 
Tr: Regulatory T cells 
UPS: ubiquitin-proteasome system  
vif: virion infectivity factor 
VL: viral load 
WHO: World Health Organization 
  
 1 
 
TABLE OF CONTENTS 
ABSTRACT ................................................................................................ II 
SOMMARIO .............................................................................................. IV 
INTRODUCTION ........................................................................................ 5 
1. HIV and Acquired Immunodeficiency Syndrome (AIDS): Origin and 
History ....................................................................................................... 6 
2. HIV Virology .......................................................................................... 7 
2.1 HIV classification and structure ................................................................. 7 
2.2 HIV Structure and Genome ....................................................................... 7 
2.3 HIV life cycle .............................................................................................. 10 
3. HIV pathogenesis: transmission and progression ........................... 13 
4. Highly Active Antiretroviral Therapy (HAART) .................................. 15 
5. HIV immunology .................................................................................. 20 
5.1 Innate response to HIV infection ............................................................. 20 
5.2 Adaptive response to HIV infection ........................................................ 21 
5.2.1 Cellular Immune Response .............................................................. 21 
5.2.2 Humoral Immune Response ............................................................ 23 
6. Models of Natural Protection ............................................................. 24 
6.1 Genetic correlates of protection .............................................................. 27 
6.1.1 Candidate-gene studies .................................................................... 27 
6.1.2 Immune correlates of protection ...................................................... 32 
7. Antigen processing and presentation ............................................... 33 
7.1 Endogenous antigen presentation pathway .......................................... 34 
7.2 Exogenous antigen presentation pathway ............................................ 36 
7.3 Cross-presentation of exogenous antigens .......................................... 38 
7.4 The MHC class I ........................................................................................ 39 
7.5 The ubiquitin-proteasome system .......................................................... 41 
 2 
 
7.6 Peptide transport across membranes .................................................... 43 
7.7 The peptide-loading complex .................................................................. 44 
7.8 N-terminal trimming of peptide precursors ............................................ 44 
8. Endoplasmic Reticulum Aminopeptidases ....................................... 45 
8.1 ERAP1 structure and its variants ............................................................ 47 
8.2 ERAP2 structure and its variants ............................................................ 48 
8.3 Trimming activity of ERAP1 and ERAP2 ............................................... 50 
8.4 Localisation/secretion of ERAP1 and ERAP2 ...................................... 53 
9. Alteration of ERAP function in human diseases .............................. 54 
9.1 Hypertension .............................................................................................. 54 
9.2 Bacterial and Viral infections ................................................................... 55 
9.3 Autoimmune diseases .............................................................................. 56 
9.4 Cancer......................................................................................................... 56 
9.5 Cytokine Receptor Shedding ................................................................... 58 
10. Non-immunological function of ERAP ............................................. 59 
AIMS ......................................................................................................... 60 
MATERIALS AND METHODS .................................................................. 63 
1. Role of ERAP2 variants in HIV1-infected ART-treated patients 
(ICONA Cohort) ....................................................................................... 64 
1.1 Sample collection ...................................................................................... 64 
1.2 Genotyping analyses ................................................................................ 64 
1.3 Statistical analyses ................................................................................... 65 
2. Role of ERAP2 in vitro HIV-1 infection .............................................. 66 
2.1 Sample collection ...................................................................................... 66 
2.1.1 Isolation of PBMCs ............................................................................ 66 
2.2 Genotyping ................................................................................................. 67 
2.3 Cell cultures and in vitro HIV-infection ................................................... 67 
2.4 p24 ELISA .................................................................................................. 68 
 3 
 
2.5 RNA extraction, DNAse treatment and retrotranscription ................... 68 
2.6 Real Time PCR .......................................................................................... 69 
2.7 Cytofluorimetric analysis .......................................................................... 70 
2.8 Statistical analysis ..................................................................................... 70 
3. Trimming function of ERAP2 variants ............................................... 71 
3.1 ERAP2 DNA construct generation.......................................................... 71 
3.1.1 Site Directed Mutagenesis (SDM) ................................................... 71 
3.1.2 V5-tag 2 step SDM ............................................................................ 73 
3.1.3 Ethanol Precipitation.......................................................................... 74 
3.2 Overlap extension PCR cloning: ERAP2 AS ........................................ 74 
3.2.1 Restriction enzyme digestion ........................................................... 75 
3.2.2 DNA ligation ........................................................................................ 75 
3.3 Cloning of DNA constructs ....................................................................... 76 
3.3.1 Bacterial transformation .................................................................... 76 
3.3.2 Screening of bacterial colonies ........................................................ 76 
3.3.3 Maxiprep .............................................................................................. 77 
3.4 Cell based functional assessment of ERAP2 constructs .................... 77 
3.4.1 Cell culture and maintenance .......................................................... 77 
3.4.2 Transfection of variant model constructs for ERAP2 ................... 78 
3.4.3 T cell activation assay ....................................................................... 79 
3.5 Molecular Biology ...................................................................................... 80 
3.5.1 Cellular Supernatants concentration ............................................... 80 
3.5.2 Immunoprecipitation (IP) for V5 tag ................................................ 80 
3.5.3 Immunoblotting ................................................................................... 81 
3.5.3.1 Preparation of cell lysates ............................................................. 81 
3.5.3.2 SDS-PAGE gel ................................................................................ 82 
3.5.3.3 Blocking and immunodetection .................................................... 82 
 4 
 
RESULTS ................................................................................................. 84 
1. Role of ERAP2 variants in HIV1-infected treated patients (ICONA 
Cohort) ..................................................................................................... 85 
1.1 Clinical parameter analysis of the ICONA cohort subjects ................. 85 
1.2 Analysis of allelic variants in the ICONA cohort ................................... 87 
1.3 Correlation between single allelic variants and clinical parameters 
(CD4+/CD8+ T cell count and Viral Load) ................................................... 89 
1.4 Correlation between combined allelic variants and clinical parameters 
(CD4+ or CD8+ T cell count and Viral Load) ............................................... 93 
2. Role of ERAP2 in in vitro HIV-1 infection .......................................... 96 
2.1 ERAP2 Inhibition increases susceptibility to in vitro HIV-1 infection . 96 
2.2 rhERAP2 addition in the extracellular milieu reduces viral infection 
and/or replication ........................................................................................... 100 
3. Trimming function of ERAP2 variants .................................................... 102 
3.1 Hap B models show a reduced trimming activity compared to 
ERAP2 wt (Hap A) ..................................................................................... 102 
3.2 The different trimming activity of Hap A and Hap B results in a 
different T cell response ............................................................................... 105 
3.3 ERAP2 localization (preliminary results) ............................................. 107 
DISCUSSION AND CONCLUSIONS ...................................................... 110 
REFERENCES ....................................................................................... 117 
SCIENTIFIC PRODUCTS ....................................................................... 142 
Abstracts ............................................................................................... 143 
Publications .......................................................................................... 144 
 
 
INTRODUCTION 
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
  
INTRODUCTION 
 
6 
 
1. HIV and Acquired Immunodeficiency Syndrome 
(AIDS): Origin and History  
In 1980s for the first time, the human immunodeficiency virus (HIV) infection 
was described. In 1983 Barré-Sinoussi-Montagnier and, one year later 
Robert C. Gallo, demonstrated the existence of a new retroviral virus and its 
relation, as causative agent, with the acquired immunodeficiency syndrome 
(AIDS). Fourteen years later, in 2008, Barré-Sinoussi and her boss Luc 
Montagnier received the Nobel Price for this discover [1-3].  
HIV was first found and described in Africa [4-5]. Kreiss JK et al., 
demonstrated an epidemic HIV status in East Africa explained by the 
presence of high percentage of seroposivity prostitutes in Nairobi [6].  
Despite a slight reduction in new infection in recent years, the problem of 
prevention, drug treatment and adverse effects is still enormous. The impact 
of morbidity and mortality caused by HIV infection is high despite the 
availability of antiretroviral therapies. The World Health Organization (WHO) 
data report 1.6 millions of people dying for the disease every year and still 
30 million living with HIV infection, most of them (70%) in Africa. It is 
estimated that HIV has infected 50 - 60 million people, causing death of more 
than 25 million individuals [7-8]. The presence of the virus causes a severe 
immunodeficiency condition, characterized by CD4+ T cell loss, leading to 
secondary effects as co-infection (by other pathogens like mycobacterium 
tuberculosis and hepatitis viruses), dementia and malignant tumours (mostly 
Kaposi’s Sarcoma and B-cell lymphoma). Without a therapy, HIV-infection 
leads to Acquired Immunodeficiency Syndrome (AIDS) and ultimately to 
death. 
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2. HIV Virology 
2.1 HIV classification and structure 
HIV is a retrovirus belonging to viral retroviridae family and to the genus 
Lentivirus. Two different types of HIV have been identified: HIV type 1 and 
HIV type 2. They differ for genome structure but both cause AIDS syndrome. 
HIV-1 is more prevalent in America, Europe and Central Africa, while HIV-2 
is present in West Africa and in Asia [8-10]. HIV-1 raised from cross-species 
transmission of a chimpanzee virus to humans and, based on genome 
differences, three groups of HIV-1 have been described: M, N and O [11]. 
Group M can be divided into 11 major clades (A1, A2, B-D, F1, F2, G-K) and 
most of HIV infections are due to them. Circulating recombinant forms (CRF) 
contribute to maintain and expand the diversity of HIV subtypes. Clades A1, 
D and CRFs are predominant in Kenya, whereas clade B is prevalent in North 
America and Europe [12].  Ten years ago, a new HIV-1 sequence was 
isolated from a single individual. Result show a stronger similarity between 
the sequence and a simian immunodeficiency virus (SIV) found in gorillas, 
compared with SIVs found in chimpanzee. The sequence has been placed 
in group P “pending the identification of further human cases” [13].  
As for HIV-2 origin, it raised up from cross-species transmission of a sooty 
mangabey virus. The genomic structure and antigenicity is different and it 
has a lower infectivity, causing a slower progression of the disease compared 
with HIV-1 [14-16].  
2.2 HIV Structure and Genome  
HIV-1 is a single-stranded RNA (ssRNA) enveloped virus with a spherical 
shape and dimension about 100 nm; The genome contains two identical 
positive sense single-stranded RNA molecules (~ 9.2 kb long) and localizes 
into a capsid of p24 viral proteins surrounded by p17 matrix proteins. A cell 
INTRODUCTION 
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membrane host-derived phospholipid bilayer envelope packs the viral 
structure [17] (Figure 1.1). 
Long terminal repeats (LTRs) in the viral genome regulates survival functions 
for the virus as viral replication, integration into host genome and gene 
expression. Structural genes encode the infection-envelope (Env) 
glycoprotein (gp) 120 and gp41, internal core (Gag) proteins and the 
enzymatic polymerase (Pol) necessary for viral replication. In detail, 
polymerase sequence encodes for reverse transcriptase (RT), integrases 
(IN) and protease (PR). There are also regulatory genes, such as Tat and 
Rev, and accessory genes like Vif, Vpr, Vpu and Nef [18].  
 
Figure 1.1. HIV-1 Structure. HIV-1 virion binding to a T cell through the CD4 and 
other chemokine receptors on the target cell surface. Image from “Cellular and 
Molecular Immunology, 8th Edition” [17].  
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Vif is the acronym of “virion infectivity factor” and it relates with viral infectivity; 
Nef is a virion–associate protein, the deletion origins an asymptomatic 
infection in macaques [19-21]. Vpu is present only in HIV-1 and shares 
similar functions with nef and gp120-env. It down regulates CD4 molecules 
from the plasma membrane of infected cells. Further Vpu counteracts BST-
2 (or Tetherin), a cellular protein which hampers the release of new progeny 
virions in the final step of the virus life cycle [22-23] (Figure 1.2).  
Only in HIV-2, the presence of the virion-associated protein Vpx facilitates 
virus replication in T cells and macrophages by counteracting the host factor 
SAMHD1, which hydrolyses intracellular deoxynucleoside triphosphates 
(dNTPs) required for the synthesis of viral DNA [24].  
Tat and Vpr (virion–associated protein) are transcriptional activators of HIV-
1, in particular in non-dividing cells such as mature macrophages [25]. 
Besides Vpr’s control at cellular level (apoptosis and G2/M cell cycle arrest), 
it makes part of pre-integration complex (PIC). PIC chaperons the viral 
genome into the cell where conversion from RNA to DNA by virion–
associated reverse transcriptase enzyme takes place (nucleus).  
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Figure 1.2. HIV-1 genome. For each gene, a different colour is associated. The 
common sequence used by different genes is shown by overlapping blocks. Genes, 
whose code separate sequence and require RNA splicing to produce mRNA, are 
related to coloured block separated by lines. Image from “AIDS and the immune 
system” [26]. 
 
2.3 HIV life cycle 
In HIV infection, the first step for the virus’ entrance is the bond between the 
viral protein gp120 and CD4 molecules present on the surface of host target 
cells. The bond induces a conformational change followed by a second bond 
between another gp120 protein and the co-receptors CCR5 or CXCR4, 
depending on viral tropism. R5X4 HIV variants are able to bind both 
described chemokine receptors, X4 variants use CXCR4 coreceptor, while 
R5 variants bind CCR5 chemokine receptor [27]. CCR5 is expressed on 
macrophages and activated T-cells, while CXCR4 expression is ubiquitous. 
This bound induces the presentation of a hydrophobic region that starts the 
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fusion process between the virus envelope and target cell membrane. Once 
the cell is infected, different gp120 and gp41 proteins are shown on the 
cellular surface, thus favouring cell-cell fusion, by receptor bindings and new 
infections (Figure 2.3) [28]. Once inside, the reverse transcription process 
starts via enzyme activation: the viral reverse transcriptase converts RNA 
genome into a single stranded (ss) DNA copy immediately replicated to 
produce a double stranded (ds) molecule [29]. The reverse transcription 
process is error-prone and it allows to increase the diversity of progeny 
genomes. Subsequently, the viral dsDNA enters into cell nucleus with the 
viral integrase which catalyses the insertion of the viral DNA into the host 
genome (provirus) [17; 30-31]. The provirus could stay transcriptionally 
inactive long time (months or years) and this explains the latency of HIV 
infection for long periods in infected individuals. 5’ LTR sequence (containing 
polyadenylation signal sequences -TATA box promoter sequence) regulates 
the transcription process, induced by cytokine-mediated T cell and 
macrophage activation . Cytokines like interleukin (IL) 1, IL-3, IL-6, TNF, 
interferon γ (IFN-γ) and granulocyte-macrophage colony-stimulating factor 
(GM-CSF) stimulate HIV gene expression in infected macrophages, while IL-
2 and tumor necrosis factor (TNF) stimulate HIV gene expression in infected 
T cells [32-37]. Inter-individual variants may play a key role in conditioning 
HIV replication and the pathogenesis of AIDS because the physiological 
response of latently infected cells to exogenous stimuli may increase viral 
replication and spread, favouring infections in new cells.   
We can divide HIV gene expression into two stages: an early one, where 
regulatory genes are expressed and a late stage, in which structural gene 
expression takes place. 
After transcription, viral polyproteins are translated in the host cell cytoplasm 
and cleaved, by a mix of viral and cellular proteases, into individual viral 
INTRODUCTION 
 
12 
 
proteins. Soon after, the assembly of infectious viral particles starts and is 
followed by budding from the plasma membrane of progeny virions [27] 
(Figure 1.3). Viral full-length RNA transcripts are packaged within a 
nucleoprotein complex (gag core proteins and pol encoded enzymes) and 
during bud-process env and host glycoproteins are included in the viral 
envelope. 
Notably, some host cells may express prevent-virion release factors, such as 
APOBEC3 (Apolipoprotein B mRNA editing enzyme catalytic polypeptide like 
3) which interferes with viral replication [17]. Another example is represented 
by TRIM5α a host factor identified in 2014 by Edward Campbell, which brings 
in non-human primates to viral transcriptase’s proteosomal degradation and 
premature viral uncoating [38]. 
 
Figure 1.3. Schematic representation of HIV life cycle. Image from “The structural 
biology of HIV-1: mechanistic and therapeutic insights” [39]. 
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3. HIV pathogenesis: transmission and progression 
HIV-transmission from one individual to another may occur by different 
routes. Among horizontal transmission, the most common is sexual contact: 
homosexual or heterosexual. The latter accounts for the majority of HIV 
cases worldwide [40]. 
Follow parenteral transmission by needle sharing and blood contaminated 
transfusions, although nowadays the index of infections due to contaminated 
blood products is significantly decreased compared with the past because of 
routine laboratory screenings.  
Nowadays it is also possible to prevent vertical transmission, which occurs 
when the virus passes from mother to child during pregnancy (in utero) or 
postnatal life (trough breast-feeding). Treating the mother with antiretroviral 
drugs during the prenatal period prevent the transmission.  
Three different phases characterise HIV-infection and progression in 
absence of antiretroviral therapy (ART): acute phase, chronic phase and 
AIDS (Figure 1.4). Three months after the transmission, infected individuals 
may undergo to non-specific symptoms of infection, such as acute 
mononucleosis-like syndrome, which occurs in 50-70% [17]. At this primary 
stage, the immune system is not able to control and contrast the infection, 
and therefore viremia peaks are commonly observed. HIV usually enters into 
the host via mucosal epithelia where it causes a rapid lymphocyte depletion 
infecting memory CD4+ T cells in mucosal lymphoid tissues. Moreover, 
epithelial dendritic cells, which are able to capture the virus, migrate into 
lymphnodes where, by direct cell contact, can infect CD4+ T cells increasing 
viremia levels. At this condition, HIV can spread across the body and infect 
helper T cells, dendritic cells and macrophages.  
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In the meantime the immune system progressively develops an HIV-specific 
humoral and cell-mediated immune response which partially control the viral 
spread and infection causing a sharp drop in viral load more or less 12 weeks 
after primary infection. This low point in viral load (VL set point) has been 
positively associated with the progression of HIV-disease: the higher the VL 
of the set point, the faster the virus will progress to AIDS; the minor the VL 
of the set point, the longer the patient will persist in clinical latency [41-42].  
A longer chronic phase follows acute infection. Even if HIV-1 is still present 
in organs like lymphnodes and spleen, the immune system seems to become 
competent at managing various infections. Actually a consistent CD4+ T cell 
turnover and a progressive decline of these cells in the periphery take place. 
The more the disease progresses the more the host becomes susceptible to 
new infections. The presence of opportunistic infections, that the immune 
system attempts to cope with, facilitates HIV-1 replication.  
Two-hundreds cells/mm3 CD4+ T cell count is the threshold that marks the 
onset of AIDS and it is considered the final and lethal phase of the disease. 
During this stage, the host immune system is unable to contrast new 
opportunistic infections and infectious challenges [43]. The immune system 
is severely depleted and usually secondary effects (as neoplasms, central 
nervous system degeneration and kidney failure) lead to death [44-45]. 
However nowadays, the natural course of HIV-infection has been deeply 
modified by the availability of an efficient antiretroviral therapy that has 
improved the course of disease as well as time and quality of survival of the 
patients. 
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Figure 1.4. Natural course of HIV-infection. Image from ”The Immunopathogenesis 
of Human Immunodeficiency Virus Infection” [44]. 
4. Highly Active Antiretroviral Therapy (HAART)  
Antiretroviral drugs, able to inhibit HIV replication cycle at different levels, are 
used to control and manage HIV-infection. In 1987 zidovudine (AZT) was 
approved as first antiretroviral drug by the US Federal and Drug 
Administration. In the following years, different antiviral drugs were 
discovered and approved for the treatment of HIV-infection. In the 90s a 
“combinational antiretroviral therapy”, consisting of 3-drug therapy into 
clinical practice, leaded to an AIDS rate’s decline (80%), reducing 
hospitalization and death in HIV-infected patients. Basically, introduction of 
ART transformed HIV-infection from being a fatal condition to a chronic and 
non-fatal one [46]. 
We can classify antiretroviral drugs in 6 different groups according to their 
action mechanism in viral life-cycle:  
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 Nucleotide reverse transcriptase inhibitors (NRTIs): as the name 
suggests, these drugs are able to prevent HIV-replication, inhibiting 
viral reverse transcriptase. NRTIs act as competitive inhibitors by 
blocking nucleosides addition to the DNA chain during the HIV 
transcriptional process. Commercial drugs belonging to this group 
are Abacavir (ABC), Emtricitabine (FTC), Lamivudine (3TC), 
Stavudina (d4T), Tenofovir (TDF) and Zidovudine (ZDV). 
 
 Non-nucleoside reverse transcriptase inhibitors (NNRTIs): also this 
category of drugs is able to prevent HIV-replication, however their 
mechanism of action is different from NRTIs. Indeed they are able to 
interfere with reverse transcriptase viral activity, binding the 
hydrophobic pocket p66 subunit of the enzyme and leading to a 
conformational change that blocks the catalytic site of the reverse 
transcription enzyme. First generation commercial NNRTIs are, for 
example, Nevirapine (NVP) and Efavirenz (EFV), instead Rilpivirine 
(TMC278) and Etravirine (TMC125) are considered second-
generation drugs. HIV-2 presents a natural resistance to this type of 
drugs.  
 
 CCR5 antagonists: CCR5 chemokine receptor is a co-receptor used 
by R5 HIV to enter into host cells. These antagonists act by binding 
the chemokine receptor and resulting in a virus internalization 
inhibition. The use of this drug could shift HIV tropism, allowing HIV 
to target CXCR4 (the other main co-receptor) so some cautions are 
requested when using these drugs. Maraviroc (MVC) is a CCR5 
antagonist.  
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 Fusion Inhibitors (FIs): drugs belonging to this category block HIV-
fusion with the cellular membrane of target cells and virus entry 
process by competing with gp41. Enfuvirtide (ENF) belongs to this 
class. 
 
 Integrase strand transfer inhibitors (INSTI): These drugs block the 
integration of HIV-genome into host cell’s genome. Raltegravir (RAL) 
and Elvitegravir are INSTI drugs.  
 
 Protease inhibitors (PIs): Viral proteases are responsible of the 
packing (and make infective) of new virions. This class of drugs is 
able to prevent and to inhibit this process.  Atazanavir (AZT), 
Darunavir (DRV), Fosamprenavir (FPV), Indinavir (IDV), Lopinavir 
(LPV), Nelfinavir (NFV), Ritonavir (RTV), Saquinavir (SQV) and 
Tipranavir (TPV) are all PI. 
 
 
Mono-therapy showed to be unsuccessful because a single inhibition 
mechanism favours the onset of new mutant resistance virus. This could be 
explained by an intense HIV genetic variability together with a selective 
pressure induced by the drug.  
The use of two NRTIs plus one NNRTIs or a combination of two NRTIs plus 
one PI, defined as Highly Active Antiretroviral Therapy (HAART), is the 
current therapeutic approach used as standard antiretroviral regimen. It is 
based on the administration of a combined therapy, which hinders different 
stages of viral replication to achieve a synergistic effect in infection control. 
As a matter of fact, the approach based on a combined therapy suddenly 
increases CD4+ T cell counts and, at the same time, brings to a stable and 
drastic viral load suppression. In general, HAART efficacy is achieved in 4-6 
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months after initiation with an increase of 100-150 cells/mm3/year of CD4+ 
T cell count and a suppression of viral replication (< 50 copies/ml) [47-49]. 
That being said, at the time of HIV-diagnosis current medical guidelines 
suggest to perform a genotype drug resistance test in order to opt to the right 
and more effective combination of antiretroviral drugs. As expected, the 
success of therapy depends on the patient’s adherence to the treatment 
regimen and one of the most common causes of suboptimal adherence is 
poor tolerability of ART treatment. 
As all the therapies, ART has side adverse events. Anaemia, diarrhoea, 
dizziness, headaches, fatigue, nausea, vomiting, pain and nerve problems 
as well as coetaneous rashes are considered short-term effects. Instead 
among the long term effects we can list: diabetes caused by insulin 
resistance, lipodystrophy, increase in cholesterol and triglycerides levels 
(lipid abnormalities), lactic acidosis and reduction of bone density. The 
scientific as well as the medical community suggested to suspend the 
HAART regimen for shorts period in the attempt to reduce side and toxic 
events due to long-term therapy and to improve patient’s compliance. 
However, a large trial funded by National Institute of Health (NIH), called 
SMART, demonstrated more benefits following a continuous antiretroviral 
regimen compared with the risks of long-term collateral effects. Changing the 
drug regimen is one of the possibilities to avoid long-term complications of 
HAART. 
Another aspect to be considered is when starting HAART therapy. Currently 
medical guidelines suggest, the antiretroviral drug regimen should be started 
at the time of HIV-diagnosis in particular if CD4+ T cell count is less than 350 
cells/mm3. However two large randomized controlled clinical trials, named 
TEMPRANO and ART-START (Strategic Timing of Antiretroviral Therapy), 
demonstrated a reduction of morbidity and mortality among HIV-infected 
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patients with CD4 T cell count >500 cells/mm3. The studies were randomized 
in order to receive ART immediately after diagnosis versus delaying initiation 
of therapy [50-55]. Notably, some recent evidences correlate HAART with 
the prevention of HIV-infection and transmission (PrEP: Pre-Exposure 
Prophylaxis). In particular, studies on HIV-serodiscordant heterosexual 
couples show lower HIV plasma levels correlated with lower transmission 
rate as well as a decrease in the virus concentration in genital secretions [56-
58]. 
The fact that antiretroviral therapy has been universally approved, has 
allowed the development of new perspectives of study on HIV-infection. New 
cohorts of HIV-positive patients, following an ART/HAART regimen or not, 
raise up in order to analyse different aspects of the disease. The goals of 
these projects are to have interdisciplinary observations for human 
immunodeficiency virus, such as clinical trial, translational studies, basic, 
epidemiological and social sciences and, also, for addressing public health 
questions. These studies allow monitoring challenges of modern 
antiretroviral treatment (like effectiveness, drug resistance and toxicity), 
treatment-duration, virus–host interactions, cell biological and genetic 
mechanisms of the disease.  
For example, in 1988 the Swiss HIV Cohort study (SHCS) was established 
dissecting different aspects of the pathology. Other groups to be mentioned 
are the UK Collaborative HIV Cohort (CHIC) and the HIV-Brazil cohort. The 
Multicenter AIDS Cohort Study (MACS) is a US 30-year study of the HIV-1 
infection in gay and bisexual men conducted since 1984 (Retrained from: 
http://www.shcs.ch/; http://www.ukchic.org.uk/; http://aidscohortstudy.org/). 
In the Italian panorama, ICONA is a unique cohort that joins other prestigious 
European and American cohorts. It started as a Foundation in 2007 but it has 
been operating since 1997. It consists in a national Italian network designed 
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to collect clinical data and select biological materials from 50 medical centres 
operating throughout Italy and coordinated by 6 University Centres. In the 
last 20 years, more than 14.500 patients have been enrolled. Notably, the 
only eligibility criterion for participants is that they must never have taken 
antiretroviral drugs, indeed all the patients were “naïve” to antiretroviral 
therapy at the enrolment time. It, therefore, stands out as the only cohort in 
the world capable of supplying reliable data on the impact of initial treatment 
on epidemiological, clinical, biological, and behavioural parameters. 
5. HIV immunology 
The first immune system response to HIV infection is similar to the one 
mounted for other viruses, however it has a limited protection against the 
infection. 
5.1 Innate response to HIV infection 
Innate immune system provides the first line of defence mediated by the host 
system. Competent cells are able to recognize by pattern recognition 
receptors (PPR) evolutionary conserved structures known as pathogen-
associated molecular patterns (PAMPs). Among these, toll-like receptors 
(TLRs) identify conserved motifs unique to microorganisms. In terms of viral 
infection, the best characterized are TLR-9 which is specific for DNA 
molecules, TLR-7, TLR-8 and TLR-3, which recognize both single-stranded 
RNA (ssRNA) or double-stranded RNA (dsRNA) and viral proteins [59]. 
Interestingly HIV-1 ssRNA encodes for different TLR-7 and TLR-8 ligands, 
which can directly activate the immune system in vitro. The bond between 
receptor and specific-substrate triggers a cascade of cytokine production. In 
particular, the expression of interferon α (IFNα) is enhanced, followed by a 
transient increase in interleukin (IL)-10, IFNγ, tumor necrosis factor (TNF) α, 
IL-15, IL-18, IL-22, and CXCL10. IFNα is able to activate the expression of 
different genes known as interferon stimulated genes (ISG) and this process 
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is able to inhibit viral life cycle at different stages [60-61]. In vitro, the 
interferon cascade-inhibition has been demonstrated in macrophages, 
monocytes and humanized mouse models of HIV-1 infection [62]. The 
production of IL-10 and IFNγ casually correlates with the beginning of virus-
specific adaptive immune response [63]. Due to high levels of pro-
inflammatory cytokines secreted by specific cells (in particular by monocytes 
and dendritic cells), the activation and expansion of natural killer (NK) cells 
occur. This step correlates with the acute HIV-1 infection phase, which 
precedes any antibody response [64]. After an initial peak, NK levels start to 
decrease and a persisting viral replication leads to disease progression. 
5.2 Adaptive response to HIV infection 
The response of adaptive immune system is another important aspect of host 
response against HIV. It can be divided into cellular and humoral response. 
5.2.1 Cellular Immune Response 
The main cell types that play a central role in this process are T lymphocytes. 
We can identify two main clusters of T cells: T helper (Th) CD4+T cells and 
cytotoxic CD8+ T lymphocytes (CTLs). Th cells can separate into different T 
cell subsets: Th1, Th2, Regulatory T cells (Tregs) and Th17. Type 1 
cytokines like IFNγ, TNFα and IL-2 are requested for events such as 
proliferation, activation and differentiation of Th and CTLs into memory or 
differentiated cells and are produced by Th1. Humoral immune response is 
activated by Th2, mediated by IL-4, IL-5 and IL-13 secretion. A robust HIV-
specific CD4+ T cell response is associated with better control of HIV viral 
replication [65]. The detection and elimination of infected cells is made by 
CTL. The mechanism of action of these cells is associated with the 
recognition and bond of viral antigens to MHC I molecules that present them 
on the cell surface. Once activated, the production and release of perforins 
and granzymes by CD8+ T cells can directly eliminate infected cells [66]. The 
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elimination of infected cells can occur also by apoptosis following the 
interaction between Fas ligand, on CTL surface, and Fas receptor, 
expressed by infected cells [67]. As explained above few weeks after primary 
infection a decline in peak viremia occurs and it correlates with HIV-specific 
CD8+ T cell onset. These HIV-specific T cells play a key role in viral 
replication control and usually are specific for Env and Nef peptides, while 
later, during infection, CD8+ T cells specific for other viral proteins take place 
[68].  In line with this concept, CTLs isolated from HIV-infected individuals 
are able to inhibit viral replication in in vitro assay [69]. In addition, the 
depletion of CD8+ T cells from SIV-infected macaques results in a loss of 
viral control and rapid disease progression [70].  
The immune responses, in particular the cellular one, play a critical pressure 
in viral evolution explained by viral isolates able to escape from CTLs and 
CD4+ T cell control. This occurs for the loss of their original CTLs and CD4+ 
T cell epitopes [71]. However, a functional exhaustion of HIV-specific T cells 
undergoes and T cells die by apoptosis after losing proliferative and cytotoxic 
abilities. Different efforts have been made to study T-cell exhaustion 
phenomenon and factors as programmed death 1 (PD-1), cytotoxic T-
Lymphocyte Antigen (CTLA)-4, lymphocyte activation gene (LAG)-3, T cell 
immunoglobulin domain and mucim domain (Tim)-3 have been identified as 
markers of the process [72]. In support of this, PD-1 has been identified as a 
critical negative regulator in HIV-infection [73] while Tim-3 has been linked 
to elevated sensitivity to Treg-mediated suppression [74]. 
The function of Treg cells is to maintain peripheral tolerance and prevent 
autoimmune diseases and chronic inflammation. This is reached by 
suppression of antigen-specific T-cell responses and by control of immune 
activation [75]. Inhibition of antiviral immune responses contributes to 
pathogen persistence and disease progression. Conversely, Tregs help to 
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suppress immune activation, thereby slowing disease progression. Notably 
HAART increases Treg level, normally decreased with disease progression 
[76-78].  
Th17 cells produce the pro inflammation cytokine IL-17, especially at 
mucosal level [79]. In HIV population an imbalanced Tregs-Th17 ratio and 
has been described and a lot of efforts have been made to clarify the Th17 
controversial protective-harmful double meaning, however, its role in HIV-
infection is not yet fully understood [80].  
5.2.2 Humoral Immune Response  
Another force of adaptive response is represented by humoral immune 
response. Dendritic cells (DC) internalise viral proteins and process these 
into smaller viral peptides, which are shown on the membrane in order to 
activate specific humoral response. The presentation occurs mainly through 
the antigen presentation machinery Major Histocompatibility Complex (MHC) 
II that binds the viral peptide and to CD4+Th cells, which then stimulate naïve 
B cells by cytokines production. After the recognition of specific epitopes 
through surface antibodies, B cells differentiate in part into plasma cells, 
which subsequently produce specific antibodies such as IgG, IgA, IgE, the 
other part into memory B cells. The seroconversion is related to the detection 
of an antibody response to HIV that takes place within 6-9 weeks after 
infection [81]. The efficacy and neutralization power of early antibodies are 
not high, despite of it 3 months from infection proper neutralizing antibodies 
appear. However, they are not able to cope with infection progression and to 
control viremia. The most immunogenic proteins of HIV are the envelope 
glycoproteins, indeed high levels of anti-gp41 and anti-gp120 can be 
detected in HIV-infected patients for a couple of years.  
The panel of B cells in HIV-infected patients shows to have an abnormal 
distribution compared with an uninfected control. For example, a lower 
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frequency of memory B subset (CD27+B220−) and higher frequency of 
plasma blasts (CD20lo/−CD27hiCD38hi) have been reported. Additionally, 
tissue-like memory B cells (usually characterized to be exhausted cells with 
a reduced proliferation index) are shown to be increased in HIV-infected 
patients compared to uninfected controls. Nearby B cell chemotactic 
capability in HIV-patients is altered [82]. 
Non-human primate (NHP) studies demonstrated a passive protection of 
neutralizing monoclonal antibodies against virus challenge [83]. Thereby, in 
the last years a lot of efforts have been made to discover and characterize 
several highly potent antibodies to use in a not far future vaccine scenario. 
New findings from an early-stage clinical trial (based on 2600 women under 
risk for contracting HIV) of a potential HIV vaccine candidate have proven to 
be encouraging [84]. 
6. Models of Natural Protection 
As explained above, immune responses against HIV are quite complex as 
many viral and host factors, as well as individual variables, interplay [85]. 
Indeed in the world population, subjects with an unconventional 
infection/progression relationship with the virus have been identified. Among 
these, Long Term Non Progressors (LTNP) are patients who present peculiar 
virus-specific immune responses that allow them to control infection 
progression for many years, even in the absence of therapy [86-88]. HIV-
patients, called Elite Controllers, are able to maintain normal CD4+ T cell 
values and very low plasma HIV RNA levels for many years after infection 
without any therapy [89-90].  
The observation that parenteral exposure to HIV-1 does not inevitably results 
in infection became evident a few years later the explosion of the AIDS 
epidemics. In the late 80’s, epidemiologic studies showed that frequent 
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unprotected homosexual contacts did not mandatory result in a 
sereoconversion. The study has been based on a small cohort of men from 
UCLA Multicenter AIDS Cohort Study (MACS) [91].  
In addition, in 1992 Clerici described the presence of an HIV-specific T helper 
cell response in these exposed seronegative individuals, suggesting a 
relation between this resistance condition and an immunologic and/or 
genetic protection [92].  
Later, also in a Kenyan heterosexual female sex worker cohort the existence 
of differential susceptibility to HIV-infection was reported [93]. Shortly 
thereafter, protection from HIV-infection was described in health care 
workers accidentally exposed to HIV, intravenous drug users, subjects who 
have unprotected sex with their seropositive partners (in both heterosexual 
and homosexual scenario) and haemophiliacs who had received HIV-
contaminated factors during blood transfusions. The resistance has been 
shown as well in vertical transmission scenario. A particularly interesting 
cohort is represented by uninfected newborns from HIV-infected mothers. At 
the birth, most of them result uninfected (65-75%) despite being exposed in 
a constant way to an infected environment during pregnancy. The positive 
serostatus is due to a passive of maternal anti-HIV antibodies.  
Since the first decade of 2000s, many efforts were done trying to explain this 
complex phenomenon and trying to identify immunological and/or genetic 
correlates of protection. Comparative data obtained in different laboratories 
from various cohorts was problematic even because of the lack of a codified 
and clear classification of what is an exposed uninfected condition. Until that 
time, HIV-exposed uninfected individuals were referred to as exposed 
seronegatives (ESN), exposed uninfected (EU) or multiple exposed 
uninfected (MEU). In 2009 in Canada, the first International Symposium on 
Natural Immunity to HIV was organised with the intent to define the inclusion 
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criteria of the ESN individuals and consequently compare the results 
obtained from different ESN cohorts. A year later, a second meeting agreed 
upon a new classification of these individuals as HIV-Exposed Sero-
Negatives (HESN). A summary of the topics discussed within these meetings 
can be found in Journal of Infectious Diseases Volume 202 Supplement 3 
November 10, 2010 (Figure 1.5). 
Although many studies in the last years have tried to evaluate the influence 
of immunological factors on HIV-1 infection and disease progression and 
many efforts were dedicated to the identification of genetic variants that can 
confer either resistance to infection or slow disease progression, key 
information are still lacking. Indubitably, the resistant phenotype is not 
dependent on a single variable and its characterization requires 
multidisciplinary approaches as it results from a combination of genetic, 
immunological and environmental factors. 
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Figure 1.5. Different cohorts that control HIV infection are used to assess the impact 
of hereditably factors on HIV-1 infection and/or progression. The main genetic 
correlates of protection to HIV infection so far identified by candidate gene approach 
are summarized in this panel.  
 
6.1 Genetic correlates of protection 
6.1.1 Candidate-gene studies 
The first data supporting a genetic contribution in protection’s phenomenon 
dates back to 1996, when it was discovered that the homozygous variant 
allele of the CCR5 receptor (the main co-cellular receptor for R5 HIV-1 virus), 
called Δ32, gives an almost absolute protection to HIV-1 infection in vitro [94-
95]. These data have led researchers to investigate host genetic restriction 
factors that can influence host susceptibility to HIV, thus determining the 
genetic characteristics of individuals that have a peculiar response to the 
virus. 
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Candidate-gene studies are focused on genes which functions are directly 
related with HIV-1 life cycle or those genes responsible for the immune 
response against the viral infection. Consequently, the knowledge about 
gene function in HIV pathogenesis is a priori fundamental [96]. Remarkably, 
the most important restriction genes so far identified (and confirmed by 
genome wide studies) belong to the human leukocyte antigen (HLA) class 
I locus [97]. For example HLAB*27 expression seems to have an important 
role in maintaining a stable bound between gag peptide, in particular with 
arginine amino acid in position 2, and HLAB pocket. Instable B27-gag 
complex is correlated with a faster AIDS progression [98]. Another protective 
role is displayed by HLAB57. Indeed, HLAB57-restricted cytotoxic T 
lymphocytes are able to target a high variety of HIV-peptides as proven by 
different studies. The B5701 allele in Caucasian and the B5703 allele in 
Africans showed a broad cross-reactivity against both common and rare 
variants of dominant gag epitopes, associated with delayed progression of 
HIV disease [99-100]. Quite an opposite effect is exhibited by B*35 allele, as 
it has been associated with a faster progression of the disease [101]. 
Notably, B*35-Cw*04 haplotype is associated with a disease development 
only in Caucasian population, suggesting a negative influence on HIV 
pathogenesis [102-103]. 
The evidence that NK activation plays a defensive effect in HIV-infection has 
been established by different genetic studies. African HESN sex workers 
present a higher frequency of inhibitory KIR genes (in the absence of their 
associated HLA genes) and a higher rate of the AB KIR genotype, resulting 
in a stronger KIR activation. Further studies on the activating receptor allele 
KIR3DS1 bring on the defence mechanism displayed following NK activation. 
Homozygosis expression of this receptor is higher in HESN compared with 
HIV-infected controls [104], in addition Carrington reported that the presence 
of its presumed HLAB ligands brings to a stronger protective function of this 
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allele [102]. While Pelak showed that copy number variations of activating 
and inhibitory KIR influence the expansion of protective KIR3DS1+ NK cells 
in peripheral area, which in turn may determine differences in HIV-1 control 
post infection [105].   
Contradictory is the role exercised by chemokines and chemokine 
receptors on HESN phenotype. For example, ratio between CCL3L1 copy 
number and susceptibility to HIV-1 infection showed an inverse correlation 
of CCL3L1 levels with CCR5 expression on CD4+ T lymphocytes [106]. 
Additional results performed in a cohort of Human T-lymphotropic virus 
(HTLV)-2-infected individuals indicated a higher ratio of median copy number 
of CCL3L1 and the CCL3L1/CCL3 mRNA in HESN and in LTNP compared 
with healthy controls. 
APOBEC3H is part of the APOBEC3 family that includes seven subtypes (A, 
B, C, D, E, F, G, H) that are able to contribute at different levels to HIV-1 
resistance [107]. Among APOBEC3 family, an important role is played by 
APOBEC3G (A3G) which causes a replacement of G/A base in the viral 
genome and whose action is opposed by the viral protein VIF [108]. Recently, 
Cagliani et al., in a case-control association analysis, reported that an 
APOBEC3H haplotype, called HAPI, is associated with protection from HIV-
1 when it is sexually transmitted. HAPI produces a destabilized variant 
protein, which confers resistance to Vif-mediated degradation. This 
observation suggests that a protein with a lower stability may have been 
replaced by a more stable one, in order to obtain a greater ability to escape 
vif-mediated degradation [109]. 
Viral replication can be inhibited by type-I interferon (IFN) and the expression 
of a number of gene products with specific anti HIV-1 activity is induced by 
type-I IFN [110-111]. Myxovirus resistance-2 (MX2) is known as an 
interferon-induced inhibitor of viral infection. Goujon showed a modest MX2-
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mediated suppressor effect on divergent simian immunodeficiency viruses 
(SIVs) and different HIV strains but not an inhibition of other retroviruses (as, 
murine leukaemia virus (MLV) [112]. While depletion of MX2, using RNA 
interference method, reduced the anti-HIV-1 potency of IFNα [113]. 
Nowadays it has been demonstrated that MX2 interferes with viral 
replication, thus decreasing nuclear accumulation and integration of viral 
DNA. Mutations in the HIV-1 capsid protein, which is involved in nuclear 
import, can overcome the inhibition of MX2. Therefore, it has been 
hypothesized that MX2 targets the viral capsid and that it interacts with other 
cellular proteins, such as Cyclofilin A, which blocks the nuclear import of HIV-
1 [113-114]. In population studies, it has been observed a haplotype 
associated to SNP rs2074560 (G / A) that is more represented in HESN and 
the protective haplotype is determined by the homozygous GG. The results 
obtained suggest that the G allele of rs2074560 protects from HIV-1 infection 
regardless of the transmission route [115].  
Toll-like receptors is a family of receptors capable of recognizing 
stereotypical characteristics common to different pathogens. Previous 
studies reported that Peripheral Blood Mononuclear Cells (PBMCs) isolated 
from HESNs were more responsive to stimulation with TLR3 agonists (Poly 
I:C), TLR4 agonists (LPS), TLR7 agonists (imiquimod) and TLR7/8 agonists 
(ssRNA40) compared to those isolated from HIV-infected patients and 
healthy controls [116]. More recently, a study performed in two cohorts of 
HESNs with different exposure routes reported a higher frequency of TLR3 
SNP rs3775291 (Leu412Phe), which confers protection from HIV-infection. 
In vitro studies demonstrated that TLR3 SNP rs3775291 was associated with 
a control of viral replication and with an increase of the responsiveness 
induced by specific agonists [117]. The mechanism behind this protection 
needs to be better characterized, nevertheless in HESN it seems to be 
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associate with an increase in full-length form of the adaptor protein MyD88 
expression, which acts as an intracellular negative regulator of this pathway. 
In the immune response, antigen presentation plays a crucial role. Following 
this concept, many candidate genes studies put their efforts on this host 
defence pathway. ERAP2 (Endoplasmic Reticulum Associated 
Aminopepetidase type 2) is a gene involved in antigen presentation [118]. 
This enzyme cuts the amino-terminal end of peptide precursors that are 
processed in proteasomes in order to adjust their size to the pocket of HLA 
class I molecules. Therefore this process modulates the antigenic repertoire 
presented to CD8+ T lymphocytes and the subsequent immunological 
response [119]. ERAP2 has been target of long-standing balancing selection 
[120]. This process has maintained two highly differentiated ERAP2 
haplotypes at intermediate frequency in most human populations [121]. The 
two haplotypes, hereafter referred to Hap A and Hap B, differ at multiple 
variants in tight linkage disequilibrium. Hap B harbours the T allele for 
rs2549782 (Asn392Lys) and the G allele for rs2248374; this latter determines 
the activation of a cryptic splice site in intron 10 and the production of an 
alternatively spliced ERAP2 mRNA (ERAP2-AS) with an in-frame stop 
codon. Thus, the predicted protein product of Hap B-derived transcripts is a 
truncated protein of 534 amino acids, whereas the canonical ERAP2 protein, 
consisting of 960 amino acids, is encoded by a full-length mRNA (ERAP2-
FL) transcribed from Hap A. Since the frequency of haplotype A is higher in 
HESNs, it was hypothesized that this variant is able to generate a peptide 
repertoire qualitatively and/or quantitatively different, which in turn is able to 
confer natural resistance to infection. The data collected so far seem to 
validate this hypothesis [120-122]  
During HIV-1 infection and replication, each of these genes is able to act at 
different levels and the genetic variants previously mentioned modulate such 
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interactions by altering gene functionality. There are no studies and it is not 
yet known whether these protective gene variants may correlate with 
different responses to therapy in HIV-positive subjects undergoing ART.    
6.1.2 Immune correlates of protection 
There are evidences that innate immunity gives a contribution in the 
protection upon primary exposure to HIV before adaptive immunity is altered. 
NK activation, for example, has a main importance in resistance to HIV-
infection [123]. As well, there are many data demonstrating the role of TLR 
pathway in natural resistance to infection. PBMCs, isolated from HESN 
cohort, showed to be more responsive to TLR triggering by production of pro-
inflammatory cytokines and chemokines [116]. 
Further, it has been observed that secreted factors could play a role in HIV-
transmission at mucosal level. β-chemokines macrophages inflammatory 
protein (MIP)-1α, MIP-1β and RANTES compete with virus for co-receptor 
CCR5 which, results in a decrease of HIV infection in target cells [124].  
Elevated IL-22 levels are associated with resistance in HESN phenotype and 
it occurs by induction of acute–phase serum amyloid A, which downregulates 
CCR5 expression on target cells [125]. In conclusion, elevated salivary of β-
chemokines have been shown to be associated with oral sexual behaviour 
in men who have sex with men (MSM) HESN [126]. 
Different evidences have supported the association between T cell response 
and resistance against HIV infection in the last years in different HESN 
cohorts. The fundamental role of HIV-speciﬁc CTLs in resistance mechanism 
is recurring in data obtained from HESN cohorts. In the majority (>70%) of 
different HESN cohorts data shown the presence of HIV-speciﬁc CTLs cells 
at both systemic and mucosal level. This evidence is interesting because 
represents a key step in the disclosure of the resistance mechanism 
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characterizing HESN subjects. Briefly, an HIV-specific CTL response is 
possible only following a complete cycle of viral replication leading to an 
effective viral-antigen presentation mediated by human leukocyte antigen 
(HLA) class I molecule to CD8+ T cells. This means that in exposed 
individuals the infection takes place but their immune system is able to 
control and contain the infection progression still in an unknown way. 
Otherwise, the discovery of a cross-priming process, an alternative 
processing-presentation mechanism mediated by dendritic cells, might 
explain the presence of HIV-specific CTLs in absence of viral replication. 
HIV-specific CTLs isolated from HESN individuals are able to recognize 
various HIV epitopes that are different from those recognized by cells of HIV-
infected patients, which could suggest an increased efficacy of the alternative 
presentation mechanism. Additionally, HESN CD8+ T lymphocytes seem to 
be more responsive to gag-stimulation, in terms of perforin and granzyme 
production levels [127-128].  
As for humoral response, Devito et al., described HIV-specific IgA molecules 
into female genital tract (FGT) of HESN CSW and female uninfected partners 
of discordant couples [129]. As well, specific-IgA were reported in Pumwani 
sex worker cohort, unfortunately they seemed to not have virus neutralization 
activity [130]. 
7. Antigen processing and presentation 
Antigen processing and presentation mechanisms are fundamental for 
immune surveillance mediated by CTLs. The generation of peptides to 
present on MHC molecules at the cell surface is mediated by three pathways. 
The endogenous pathway plays a role in processing proteins and peptides 
derived from intracellular pathogens and it is reached through the major 
histocompatibility complex class I (MHC I) that present peptides to CD8+ 
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CTL. A second pathway, called the exogenous pathway, processes antigens 
derived from endocytosis of circulating peptides and is subsequently directed 
to lysosomes. MHC class II (MHC II) molecules present these peptides at the 
cell surface to CD4+ T cells. The last pathway to describe is the cross 
presentation pathway; interestingly, this process involves exogenous 
antigens being presented by MHC I. Briefly, in all these pathways, MHC 
molecules bind to peptides forming a complex (pMHC) that is recognised by 
antigen receptors present on the T cell surface (T cell receptor; TCR). Once 
bound this interaction allows the activation of the T cell, which eventually will 
eliminate target cells presenting the antigen. 
The MHC gene region, located on chromosome 6 in humans, encodes for 
highly polymorphic MHC molecules and is divided into three different regions: 
MHC I, II, III. Class I encodes HLA A, HLA-B and HLA-C, while HLA-DP, 
HLA-DQ, HLA-DR and HLA–DO are encoded by MHC class II region. Finally, 
MHC III encodes other immune system components involved in the 
complement system. 
7.1 Endogenous antigen presentation pathway 
As explained above, the endogenous presentation pathway is involved in 
presentation of antigen derived from endogenous proteins, such as viral 
proteins in the case of virus infection. In the cytosol, the proteasome and 
several peptidases trim peptides that are then transported by the transporter 
associated with antigen processing (TAP) protein into the endoplasmic 
reticulum (ER). For presentation, peptides need to be the correct length of 8-
10 amino acids [132-133]. Longer peptides require additional trimming in 
order to bind with a high enough affinity to the peptide binding pocket of HLA 
[133-135]. In humans, the N-terminal trimming of longer peptides is catalysed 
by two aminopeptidases, ERAP1 and ERAP2, while in mouse the process is 
mediated by ERAAP (endoplasmic reticulum aminopeptidase associated 
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with antigen processing) [136-139]. Once the peptides are the correct length 
to bind, they are loaded to MHC I molecules and the resulting pMHCI 
complex translocates to the cell surface in order to be recognised by specific 
CD8+ T cells [140-141]. The final goal is the CTL-mediated monitoring of the 
presence of ‘foreign’ peptides from invading pathogens [142]. As described, 
these events follow a multistep process and is shown below in Figure 1.6. 
 
Figure 1.6. MHC I antigen processing and presentation. Degradation of cytosolic 
and nuclear protein is proteasome-mediated and often followed by cytosolic 
aminopeptidase trimming.  TAP proteins transport peptide into the lumen of the ER. 
Alongside this, MHC I heavy chain folding occurs with the assistance of the 
chaperones calnexin and calreticulin, the peptide editor tapasin and the 
oxidoreductase ERp57 (the latter three, alongside TAP, form the peptide loading 
complex; PLC). Protein disulfide isomerase (PDI) helps in the formation of the 
disulfide bond in the α2 domain of the MHC I molecule. ERAPs trim N-terminal 
extensions from antigenic precursor, thus resulting in the generation of final pMHC I 
complex that exit the ER and translocate via the golgi to the cell surface [250]. 
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7.2 Exogenous antigen presentation pathway 
Competent antigen presenting cells (APC) are characterised by dendritic 
cells (DCs), monocytes-macrophages, B cells and thymic epithelium cells, all 
of which express MHC II molecules. The processing pathway starts with the 
internalisation mediated endocytosis through lysosomal and endosomal 
vesicles of protein antigen. In contrast to MHC class I molecules, the MHC II 
complex mediates a CD4+ T cell response. Briefly, the MHC II are 
synthesised and folded within the ER and consist in a tethered heterodimeric 
complex (α1, α2 and β1, β2). α2 and β2 bind the MHC to the membrane, 
while α1 and β1 domain define the peptide binding groove. Antigenic peptide 
lengths are longer compared with the MHC I, approximately 12-15 amino 
acids [143]. Intriguing, the two ends of the peptide binding groove are in an 
open conformation and have residues that allow longer length peptides to 
bind (Figure 1.7). 
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Figure 1.7. Endogenous peptides are internalised into endosomes. Immature α and 
β chains associate with Invariant chain (Ii) and then degrade, leaving a small 
fragment bound in the peptide binding grove (CLIP). HLA-DM allows CLIP’s 
dissociation and let the association of the αβ chain with peptide antigen for the final 
expression at the cell surface. Image from “Functional consequences of single 
nucleotide polymorphisms in ERAAP” [144]. 
 
Folded MHC II α and β chains are transported from the ER to lysosomal 
vesicles via the invariant chain, which binds through occupation of the 
peptide binding groove. Once in the lysosomal vesicles, the invariant chain 
is cleaved by a number of peptidases (e.g. cathepsins), resulting in a final 
CLIP peptide being bound. In MHC II rich vesicles called MIIC, the CLIP 
peptide is displaced by antigenic peptides, a process facilitated by HLA-DM 
and HLA-DO molecules [145]. Following the binding of stable exogenously-
derived peptide, the peptide bound MHC II molecules translocate to the cell 
surface for presentation to circulating CD4 + T cells [146].  
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7.3 Cross-presentation of exogenous antigens 
Cross presentation is a combination between the exogenous and 
endogenous antigen presentation pathways (Figure 1.8). Exogenous peptide 
antigen can be internalised, processed and then loaded (and consequently 
expressed) on MHC I. DCs and macrophages, expressing both MHC 
molecules, have the ability to internalise exogenous antigens and use this 
particular process of presentation. In the TAP-dependent pathway, 
exogenous products are internalised, by endocytosis or phagocytosis, 
transported into the cytosol and degraded by the proteasome [147]. The TAP 
protein transports them into the ER and they are loaded on to MHC I [148]. 
In the TAP-independent pathway the internalisation process is as above, but 
in this case antigens are degraded by endosomal proteases. Rock and Shen 
reported the presence of MHC I in the endosomes suggesting MHC I 
trafficking into these compartments allows loading and expression of MHC I, 
though the mechanism of trafficking is unknown [149]. An alternative 
pathway has been suggested where phagosomes containing exogenous 
antigen fuses with the ER allowing loading onto MHC I molecules [150]. 
In conclusion, understanding cross-presentation mechanisms could be 
crucial to identify vaccination strategies in infectious diseases and cancer. 
Interestingly, an enhanced immune protection, mediated by both effector 
CD4+ and CD8+ T cells, was only obtained when long synthetic peptides 
were used (compared to short peptides). Cross-presentation by DCs  was 
found to be fundamental to  inducing this long lasting T cell stimulation lead 
to eradication of tumours or infective pathogens [151-152].  
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Figure 1.8. Molecular cross-presentation pathways in DCs. Once internalised 
antigens, they undergo several degradation mechanisms (pH, cathepsins or 
proteases). At this point, optimal peptides can be directly loaded onto MHC 
molecules, while peptides that need to be further processed are transported to the 
cytosol where proteasomal degradation occurs. TAP or different transporters 
translocate peptides into the ER where they are loaded into MHC-I. Image from 
“Understanding the biology of antigen cross-presentation for the design of vaccines 
against cancer” [151]. 
 
7.4 The MHC class I 
The MHC I genes encode polymorphic membrane glycoproteins, which 
present self or non-self  peptides to CD8+T cells. As explained above, HLA 
proteins are encoded by HLA-A, HLA-B and HLA-C genes and by three less 
polymorphic genes HLA-E, HLA-F and HLA-G (expressed only in a tissue-
restricted area). MHC I has three components: two polypeptide chains, a 
heavy chain (α-chain) and a smaller invariant light chain β2-microglobulin 
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(β2m) subunit, and peptide antigen to present (Figure 1.9). The heavy 
polypeptide chain consists of three domains: α1, α2 and α3. α1-α2 domain 
folding creates the peptide-binding cleft, which is important in the modulation 
of the diversity of peptide presented. Consequently, these two domains have 
shown a highly polymorphic state in order to provide optimal T cell-mediated 
responses [153-154]. The transmembrane-domain α3 is essential for 
anchoring at the cell surface and it is non-covalently associated ß2m domain 
[155]. The invariant β2m is a member of the immunoglobulin family of 
proteins, but it is not encoded within the MHC gene region. The final 
component of MHC I is the peptide antigen. A small peptide of 8-10 amino 
acids bind to the MHC I groove following a non-covalent interaction, which 
induces conformational changes in this region [156] and defines the antigenic 
epitope that can be recognised by T cells. Once the TCR of CD8+ T cells 
recognises and binds a specific MHC I complex, a T cell signalling cascade 
is initiated and promotes the elimination of abnormal or virus-infected cells. 
MHC I folding, from an immature to a mature state, occurs within the lumen 
of the ER and, as other proteins with the same origin, are made for secretory 
pathways. This folding happens prior to engagement with the peptide loading 
complex (PLC) that consists of four main components (ERp57, calreticulin, 
tapasin, and TAP). Through interactions with the PLC, the MHC I molecule 
is loaded with peptide antigen completing the correct folding leading to the 
dissociation of the PLC and translocation to the cell surface through the 
trans-golgi [157-158]. 
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Figure 1.9. MHC class I complex consists of β2m, heavy α chains and peptide. α 
domains fold to form the peptide binding pocket (between α1 and α2 ). 
 
7.5 The ubiquitin-proteasome system 
The generation of the final component of MHC class I complex, antigenic 
peptide, starts within the cytosol of the cell, and the proteasome, a 
multicatalytic protease complex found in the nucleus and cytosol of 
eukaryotic cells and involved in non-lysosomal protein degradation, plays a 
central role in this process [159]. Poly-ubiquitinated proteins are  targetted 
for degradation through the ubiquitin-proteasome system (UPS), which is 
responsible for protein turnover and prevent aggregation of misfolded and 
unfolded proteins [160]. The 26S proteasome is the main proteolytic enzyme 
in the UPS system, and consists of a 20S multiple subunit core and 19S 
caps. The 20S subunit is responsible for the catalytic activity and forms a 
barrel shape made up of four rings, each containing seven subunits [161]. 
The two identical outer rings contain seven distinct α subunits (α1-α7) while 
the two inner rings contain seven ß subunits (β1-β7) that make a central 
chamber where proteolysis events occur. Among these ß subunits, β1, β2 
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and β5 have proteolytic activity. The two 19S caps act as regulatory ATPases 
and their role is to recognise and bind peptide targets with a polyubiquitin 
chain, with the S6 subunit of 19S cap primarily responsible for the 
recognition.  Upon recognition and binding of the  peptides to the  19S-20S 
complex, ubiquitinated targets are unfolded and then translocated into the 
core groove where they are cleaved into smaller peptide fragments [162-
163].Interestingly, inhibiting  proteasomal activity with specific drugs reduces 
the antigenic peptide supply and almost completely reduces MHC I 
presentation at the cell surface [164-165]. This further highlights the 
importance of the proteasome in antigen processing and presentation  
IFN-γ stimulation up regulates the expression of the proteasome and induces 
a change in three β catalytic subunits of the 20S proteasome. Homolog 
subunits LMP2, LMP7 and MECL1 are incorporated into the proteasome 
core replacing β1, β2 and β5 respectively [166-167]. This 20S proteasome 
with alternative active subunits is termed immunoproteasome for its role in 
the generation of antigenic peptides [168] and in vitro studies have shown a 
more efficiency of immunoproteasome in processing a number of 
immunogenic peptides for MHC I presentation. Recent in vivo studies have 
shown that the lack of all three subunits, LMP2, LMP7 and MECL1, resulted 
in an impaired presentation of antigenic peptide epitopes and an overall 
reduction (~50%) in surface MHC I expression when compared to wild type 
mice [169]. Furthermore, when assessed in vitro using synthetic fluorogenic 
substrates, the immunoproteasome showed a reduction in cleavage of acidic 
amino acids and an increase in cleavage after hydrophobic and basic 
residues, which bind more optimally to MHC I molecules [170]. IFN-γ 
stimulation can also induce an alternative regulatory subunit:  PA28 (or 11S 
REG). PA28 is a multimeric ring-shaped proteasome activator unit and can 
bind both ends of the 20S such as 19S cap [171], and appears to influence 
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the uptake and cleavage of shorter peptides and consequently play an 
important role in the generation of antigenic peptides [172-173] 
Peptides with an optimal length of 8-11 amino acids are a small minority of 
the proteasome products; usually antigenic peptides generated have a 
correct hydrophobic C-terminus although they often contain an extended N-
terminus and therefore a further processing step is required before stable 
binding on to an MHC I molecule [174]. This final peptide processing event 
occurs in the ER by specific proteases in order to generate an optimal N 
terminusand allow a stable MHC I complex formation. 
7.6 Peptide transport across membranes 
Transporter associated with Antigen Processing (TAP) protein belongs to the 
large family of ABC transporters, which utilise Adenosine Tri-Phosphate 
(ATP) to translocate substrates across membranes [175]. TAP consists of a 
heterodimer TAP1-TAP2 complex [176]. Both the ATP-hydrolysing subunits, 
TAP1 and TAP2, contain an ATP-binding cassette and transmembrane 
domains and are required for antigen translocation and incorporation into the 
PLC for the loading of peptide [177-178]. The peptide binding process is ATP 
independent but translocation into the ER requires ATP hydrolysis.  TAP 
mutants that are unable to bind ATP, are also unable to bind the peptide 
[179]. Interesting is that peptide binding and ATP hydrolysis of TAP are each 
targeted by several different viral immune-evasion proteins [180]. The 
translocation of peptides by of TAP can be inhibited by these viral proteins, 
such as ICP47,a protein encoded from the Herpes simplex virus.. The effect 
of ICP47 on TAP transport subsequently reduces peptide supply to nascent 
MHC I, and this inhibition of function correlates with a loss of MHC I 
expression in malignant cervical carcinoma [181]. It is well characterised that 
peptide transporters are selective for both length and the N- and C-terminal 
structure [182].  In humans, a hydrophobic C-terminal is favoured by TAP, 
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although basic residues can also be accommodated, and the optimal 
peptides length for translocation into the ER is between 8 and 16 residues. 
However, despite these length preferences, longer peptide substrates can 
be transported through TAP, albeit with lower efficiency [183].  
TAP associated glycoprotein (tapasin) is a 48kDa glycoprotein that plays an 
important role in the generation of stable peptide-MHC I complex through its 
role as a peptide editor. [184]. Tapasin serves as a bridge between MHC I, 
TAP and calreticulin, however also act as quality controller of peptides [185]. 
In  tapasin deficient cells,  a reduction of MHC I expression is observed and 
correlates with subsequent decrease in stability and ability to present peptide 
antigens, highlighting the crucial role of tapasin in the optimisation of peptide 
cargo for stable pMHC I expression [190]. 
7.7 The peptide-loading complex 
As previously discussed, the folding and peptide loading of MHC I molecules 
occurs in conjunction with the peptide loading complex (PLC). PLC is a 
multisubunit structure in the ER containing TAP assembled with MHC I, ß2m, 
tapasin, calrecticulin, ERp57, and possibly protein disulfide isomerase (PDI) 
[186-187]. Tapasin, ERp57 and PDI are fundamental for TAP stabilisation 
and control the disulfide bod in the peptide-binding groove of the MHC I 
heavy chain [188]. PLC dissociation occurs immediately after stable peptide 
loading and the pMHC I complex  is released and transported (via trans-
Golgi) to the cell surface. As expected, deficiency or alterations in expression 
of any of the components of the PLC can result in severe consequences on 
1) expression levels, 2) overall stability and 3) quality of the pMHC I repertoire 
expressed at the cell surface [189].  
7.8 N-terminal trimming of peptide precursors 
Due to the preferences of TAP in transporting peptides between 8-16 amino 
acids in length into the ER, and the optimal peptides for stable loading onto 
INTRODUCTION 
 
45 
 
MHC I being 8-11 amino acids in length, further trimming of peptides are 
often required after proteasome cleavage but before peptides can be loaded 
on to MHC I molecules [188]. Interestingly, in the cytosol, peptides of >15 
residues can be further processed by cytosolic peptidases such as tripeptidyl 
peptidase II (TPPII), leucine aminopeptidase (LAP) and bleomycin hydrolase 
(BH). LAP was firstly identified as an IFN-γ inducible cytosolic protease [191] 
and cells deficient in LAP expression demonstrate that this aminopeptidase 
can trim peptide precursors, however its activity may not be responsible for 
the generation of MHC I peptide ligands [192]. BH is a cytosolic cysteine 
protease, which can influence some antigenic peptide presentation, even if 
with a largely redundant effect in presence of other aminopeptidases [193]. 
However, despite the presence of cytosolic proteases, a subset of peptides 
can directly translocate into the ER lumen by TAP. Within the ER, the N-
terminus of these proteins may be further processed by resident 
aminopeptidases. ERAP1 and ERAP2 in humans, and ERAAP in mice, 
provide this final ER trimming process in order to create optimal length 
peptides (8-11 amino acids) to bind and load on MHC I molecules, with 
potential to result in pMHC I specific NK cell CD8+ T cell responses [137]. 
The human ER aminopeptidases, in particular ERAP2, is a major focus of 
this study, and a better characterisation of these will be discussed in more 
detail below. 
8. Endoplasmic Reticulum Aminopeptidases 
Proteasome/immunoproteasome-derived peptides are often N-terminally 
extended upon entering the ER, and consequently ER proteolysis and 
processing events occur to generate the optimal N-terminal for MHC I 
binding. In 1995, Elliot et al., identified a proteolysis phenomena within the 
ER compartment, which suggested that the peptide trimming process is not 
restricted solely within the cytoplasm [194]. In 2002, two independent groups 
INTRODUCTION 
 
46 
 
identified aminopeptidases responsible for N-terminal peptide trimming:  ER 
aminopeptidase associate with antigen processing (ERAAP) in mice and in 
ER aminopeptidase (ERAP1) in human. Approximately one year after these 
initial ERAP1 studies, a closely related ER aminopeptidase (ERAP2) in 
humans was discovered. [136; 139; 195]. ERAP proteolytic activity has been 
shown to depend on the length of the peptide substrate, with studies 
revealing that upon incubation with shorter 8mer peptides, the trimming 
activity of ERAP1 ceased, when compared to incubation with peptides longer 
in length. This substrate length dependency of ERAP is related to the fact 
that peptides of 8-9 amino acids confer a higher affinity of MHC I binding 
[138]. Importantly, ERAP aminopeptidase activity cannot be compensated by 
any other aminopeptidases within the ER, revealing the exclusive role of 
ERAP in production of MHC I ligands [196]. 
Mouse ERAAP and human ERAP1 and ERAP2 are members of zinc 
metalloprotease family and belong to oxytocinase M1 subfamily that  share 
consensus zinc-binding motif within the active site that is fundamental for 
enzymatic activity [215]. These aminopeptidases are normally expressed in 
a variety of tissues, preferentially where there is a high expression of MHC I 
molecules and are strongly induced after stimulation with IFNγ and TNFα 
[195]. After IFNγ treatment, an increase in N terminal aminopeptidase activity 
was seen in comparison to limited antigen processing in the absence of 
stimulus [197]. 
Mouse ERAAP and human ERAP1 share 86% homology, most conservation 
is seen in the active site regions [198]. Interestingly, ERAP2 has no 
equivalents in rodents, and evolution studies suggest a relatively recent 
duplication origin from ERAP1 [119]. ERAP primarily resides within the lumen 
of the ER, where they carry out their main function of peptide trimmers, and 
have been shown to localise with proteins containing the KDEL ER retention 
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motif [199]. In addition, the involvement of ERAP1 in shedding of cytokine 
receptors, and also in the regulation of innate immune and inflammatory 
responses has been observed [200]; conversely, there are no reports of 
ERAP2 participation in cytokine receptor shedding. Other cellular and 
regulatory functions of ERAP1 and ERAP2 include promotion of 
angiogenesis and blood pressure regulation through their role in cleavage of 
bioactive peptide hormones in the renin-angiotensin system [201]. The 
nomenclature ERAP1 and ERAP2 have been approved by the Human 
Genome Organization Nomenclature Committee, however ERAP1 is also 
known as adipocyte-derived leucine aminopeptidase (A-LAP), 
puromycininsensitive leucine-specific aminopeptidase (PILS-AP), or 
aminopeptidase regulating type I TNF receptor (TNFR1) shedding (ARTS-
1), whereas ERAP2 is known as leukocyte-derived arginine aminopeptidase 
(L-RAP). These alternative names relate to the different proposed biological 
functions of ERAP1/2. 
8.1 ERAP1 structure and its variants 
The ERAP1 gene is located on the long arm of chromosome 5q15 and the 
derived protein consists of 941 amino acids, with a molecular weight of 
106kDa. Among the 20 exons spanning 47 kilo-bases, exon 6 contains the 
active site region of the protein which includes the zinc metalloprotease 
catalytic motif HEXXH(X)18E, and a 5 amino acid GAMEN motif, which is 
responsible of enzymatic function [199; 202]. Moreover, differences in the 
exon 20 sequence can generate two isoforms of ERAP1: a longer isoform a 
(ERAP1a) and the shorter isoform b (ERAP1-b); this latter has found to be 
more abundant in several cells [203].  
The crystal structure of ERAP1 shows an open conformation in absence of 
peptide, revealing a large internal cavity where GAMEN and HEXXH(X)18E 
motifs are present. A closed conformation of ERAP1 has also been described 
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when bound with the protease inhibitor bestatin, however currently there are 
no crystal structures that include full length peptide binding to ERAP1. Based 
on these observations, a plausible mechanism of activity has been 
hypothesized, in which ERAP1 is peptide receptive in the ‘open’ 
conformation and when bound with the substrate, leads to a conformational 
alteration and results in the ‘closed’ conformation that results in catalytic 
enzyme activation and trimming [204-205]. 
Genetic variation in the coding region of ERAP1 can affect the biological 
functions. A number of SNPs have been identified and that are associated 
with disease and these resultant amino acid changes are located throughout 
the protein; rs17482078 (R725Q) and rs27044 (Q730E) located on inner 
surface of the C-terminal cavity and rs2287987 (M349V) can influence 
substrate sequence or length specificity [144]. Polymorphisms rs27044 
(R725Q), rs30187 (K528R), rs26653 (R127P) and rs10050860 (D575N) 
conduct to a conformational change that could indirectly affect both 
specificity and enzymatic activity. In particular, using synthetic peptide 
substrate and antigen precursor peptides, rs30187 and rs27044 have shown 
a significant reduction in aminopeptidase activity [206]. 
8.2 ERAP2 structure and its variants 
The ERAP2 gene is located on chromosome 5q15 between ERAP1 and 
leucyl-cystinyl aminopeptidase (LNPEP). It contains 19 exons and the two 
highly conserved motifs, the zinc binding site HEXXH and GAMEN motif, are 
encoded by exon 6, while essential E residue is encoded by exon 7. ERAP2 
shows a 49% of homology with ERAAP and ERAP1, and a 40% of homology 
with placental leucine aminopeptidase (P-LAP). The resulting 960 amino acid 
ERAP2 protein has a significantly hydrophobic N terminal region, similar to 
ERAP1, and preferentially cleave basic N terminal residues (arginine and 
lysine), however it shows no preference for peptides with hydrophobic C-
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termini. Crystal structure analyses display the same domain organisation of 
ERAP2 in comparison with ERAP1, with a central internal cavity where 
trimming processes occur [207]. Interesting ERAP2 has been shown to form 
a homodimer or heterodimer complex with ERAP1. Recently studies have 
demonstrated that this dimerization of ERAP1 and ERAP2 creates complex 
with a higher and more efficient peptide-trimming activity, resulting in an 
increase in the number of peptides trimmed [208]. 
ERAP2 gene has been target of long-standing balancing selection [120]. This 
process has maintained two highly differentiated ERAP2 haplotypes at 
intermediate frequency in most human populations [121]. The two 
haplotypes, Hap A and Hap B, differ at multiple alleles in tight linkage 
disequilibrium. As explained above, predicted protein product of Hap B-
derived transcripts is a truncated protein of 534 amino acids (ERAP2-AS), 
whereas the canonical ERAP2 protein, consisting of 960 amino acids, is 
encoded by a full-length mRNA (ERAP2-FL). The truncated version, also 
termed L-RAP, deems to be non-functional and it has been showed a lack of 
aminopeptidase activity when tested using various aminoacyl-MCAs [195]. 
The biological significance of the ERAP2-AS mRNA is currently unknown. 
Indeed, it is possible that ERAP2-AS mRNA is be translated into a ERAP2-
alternative spliced truncated protein of 60kDa, or alternatively degraded by 
non-sense mediated decay (NMD). For rs2248374 allele, A/G heterozygous 
and A/A homozygous haplotypes results in the expression of a 120KDa 
ERAP2-full length protein, detectable by western blot. Conversely a G/G 
homozygous haplotype should result in the production of ERAP2-AS protein, 
which resulted in a reduction in surface MHC class I expression when 
observed in human lymphoblastoid cell lines [120] (Figure 1.10).  
Since the frequency of the HapA was found to be higher in HESNs compared 
to the word population, it was hypothesized that this ERAP2 variant confer 
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natural resistance to HIV infection by qualitatively and/or quantitatively 
altering the peptide repertoire presented at the cell surface.  
 
Figure 1.10. The genomic organization of ERAP2 gene. The two spliced forms of 
ERAP2 are shown for Haplotype A (black) and Haplotype B (white). The different 
alleles of rs2248374 are indicated with a blue or purple circle in base position, 
respectively. Arrows indicate the premature stop- codons in the Haplotype B mRNA 
ERAP2-AS.  
 
8.3 Trimming activity of ERAP1 and ERAP2 
ERAP1 is crucial in trimming 9–16 amino acids peptides, which are 
transported into ER by TAP, to their optimal length of 8-9 amino acids [209]. 
Studies using ERAAP deficient mice have highlighted the contribution of 
aminopeptidase in generation of peptides presented on MHC class I 
molecules. In in vivo experiments using ERAAP deficient mice, the levels of 
cell surface MHC I, H-2Kb and H-2Db, are reduced and correlate with a 
decrease in specific CD8+ CTL responses [210]. Notably and as expected, 
MHC class II levels remained unaffected. Moreover, when cell surface 
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expression of all 5 MHC I molecules, H-2Kk, -Kb, -Db, -Dd, -Ld were 
assessed, they showed a significant reduction in surface expression in 
ERAAP deficient mice compared to wild type. Furthermore, immunization of 
ERAAP deficient mice with wild-type cells resulted in a potent increase of 
CD8+ T cell responses, highlighting the significant contributions of ERAAP 
in determining the peptide-MHC (pMHC) class I repertoire in both a  
quantitative and qualitative manner [211]. Of note, ERAP1 activity is reduced 
towards peptides with either the presence of proline in position 2 (X-P-Xn) 
[152], and/or with less than 8-  amino acids length which is the optimal length 
for binding to MHC I molecules [209]. However, a preference in catalytic 
activity towards lysine, leucine, asparagine and tyrosine residues has 
showed [136; 139; 199; 211].  ERAP1 presents a marked preference in 
trimming peptides with large hydrophobic C-terminal amino acids [209]. 
Despite this, the enzyme activity was also shown to be affected by the 
internal residue structure/sequence of peptides; Amino acid positions 2, 5 
and 7 were shown to be important for the peptide sensitivity of ERAP1 
processing [206]. Based on these observations, Chang et al., proposed a 
“molecular ruler mechanism” for the hypothesis of trimming activity in which 
ERAP1 binds substrates with a higher affinity hydrophobic C-terminus within 
the hydrophobic pocket, and the active site accommodates the N-terminal 
extended region, trimming the precursor in order to obtain optimal length. In 
support of this model, studies using recombinant ERAP1 and a selection of 
synthetic peptides, show a substrate length preference of ERAP1. 
The closely related ERAP2 shows a strong preference for the basic arginine 
and lysine residues located at the N terminal region of the peptide. ERAP2 
is present an overall domain I-IV organization (figure 1.11), in which domain 
IV closes into the proximity of domain II, the catalytic site, and the S1 pocket. 
This S1 pocket is the specific region where N-terminal peptide will be 
accommodated and cleaved. This domain organisation creates an internal 
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cavity where trim-function takes place within the active site. Residues 
54−271 (N-terminal domain I) exhibit a β-sandwich structure, residues 
272−546 (Domain II) have a thermolysin α/β-fold and contain the high 
conservative motifs, HExxHx18E and GAMEN. Residues 547−647, referred 
to domain III, present also as a β-sandwich conformation that acts as bridge 
between domains II- IV. In the end, domain IV (residues 648−960), an all α-
helical domain interacting closely with domain II, caps the Zn (II) catalytic site 
(Fig. 1.11). Interactions between II and IV domains create large internal 
cavity, close to the catalytic site, which has almost no access to the external 
solvent but exhibits numerous water molecules trapped inside [206]. Crystal 
structures show a different distribution of electrostatic potential in the cavity 
compared to ERAP1, suggesting distinct selective pressures in the antigenic 
peptide repertoire mediated by ERAP2. Asparagine at position 198 is 
important in the selectivity for the N-terminal specificity.  
 
Figure 1.11. Representations of ERAP1 (left) and ERAP2 (right) crystal structures. 
Cyan shows domain I, green shows domain II, orange refers to domain III in and 
domain IV is in magenta. Note the conformation of domain IV to domains I and II into 
a “open” versus the “closed” conformations. Image from “Antigenic peptide trimming 
by ER aminopeptidases Insights from structural studies” [119]. 
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8.4 Localisation/secretion of ERAP1 and ERAP2 
There is a strong body of evidence highlighting that ERAP1 and ERAP2 play 
a fundamental role in ER proteolysis and their subsequent ER localisation. 
However, the role of these aminopeptidases in other biological processes 
means that the overall subcellular localization of the two aminopeptidases 
remains debatable [136]. A cytosolic localisation of ERAP1 has been 
previously described by several studies [205]. Moreover, its role in cytokine 
shedding at the cell surface and binding the specific receptors (IL-1RII, IL-
6R and TNFR1), suggests a plausible ERAP1 translocation from its 
canonical (and described) subcellular localization in the ER. However, this 
may depend on the cell type or changes in the cellular environment (stress 
response).  In support of this idea, Goto et al., reported the secretion of 
ERAP1 after LPS/IFN-γ stimulation in a dose-dependent manner [212]. 
Interestingly, in a macrophage model (RAW264.7 cells) the secretion seems 
to be mediated through the TLR signalling pathway by induction of pro-
inflammatory cytokines IFN-β and TNF-α [213]. The authors have suggested 
a Ca2+ mediated mechanism for the secretion, in which cytokines increase 
cytoplasmic Ca2+ levels, which ultimately led to the induction of ERAP1 
secretion through calmodulin activation. All these data were obtained using 
specific inhibitor molecules such as BAPTA-AM and the calmodulin inhibitor 
W7. It is plausible that this localisation change of ERAP1 upon stimulation of 
cells with cytokines may result in its multifunctional properties within the cell 
[213] 
In early 2018, information regarding the extracellular localisation of ERAP2 
was highlighted. A multidisciplinary integrated analysis revealed an 
overexpression of ERAP2, along with others candidate genes, in papillary 
INTRODUCTION 
 
54 
 
thyroid carcinoma (PTC) and the cystic fluids counterpart, suggesting a 
possible property of change localisation also for ERAP2 [214]. 
9. Alteration of ERAP function in human diseases 
ERAP1 and ERAP2 are identified to be highly polymorphic aminopeptidases 
with numerous polymorphisms associated with the pathogenesis of diseases 
such as systemic arterial hypertension, diabetes mellitus,cervical carcinoma, 
preeclampsia, psoriasis and ankylosing spondylitis [215-217]. SNPs within 
these genes may result in an altered ERAP1 / ERAP2 function which can 
lead to an altered presentation process of pathogen-derived peptides, 
leading to an inadequate immune responses and disease development. 
9.1 Hypertension 
The Lys528Arg (rs30187) polymorphism in ERAP1 has shown a strong 
association with a reduction in bone mass density in a premenopausal 
Japanese women cohort. Moreover, a screening-study for 33 polymorphisms 
within ERAP1 gene, has related K528R SNP to an essential hypertension 
condition, causing by a hypothesised reduction in bradykinin formation 
and/or a lower angiotensin II inactivation [215;220]. In support of the latter, 
functional studies assessed K528R mutant activity using L-AMC substrate, 
and revealed a decrease in enzymatic activity. Collectively, a 60% reduction 
in the cleavage of both angiotensin II and kallidin hormones  into angiotensin 
III and bradykinin respectively, supports the idea of the essential 
hypertension is due to a reduced ERAP1 enzymatic activity due to the 
presence of K528R [221]. 
Hypertension is associated with a number of morphological changes. Among 
these, left ventricular hypertrophy, during anti-hypertensive treatment in 
hypertension patients, has been associated with the K528R variant of 
ERAP1 [222].  Furthermore, a genetic link has been observed between  
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altered ERAP2 expression in first trimester placentas of pregnant women and 
development of pre-clampsia, which is a heritable pregnancy disorder 
characterised by new-onset hypertension and proteinuria. This association 
with ERAP1 expression and pre-eclampsia has been confirmed a Norwegian 
and Australian cohort study [218; 223], and more recently, a genetic variant 
(rs2549782) of ERAP2 has been found to be associated with an increased 
risk of preeclampsia [224]. 
9.2 Bacterial and Viral infections 
ERAP1 plays an important role in immune response to viruses. Studies in 
ERAAP deficient mice have shown marked differences in specific 
lymphocytic choriomeningitis virus (LCMV) CD8+ T cell responses when 
compared to wild type mice. In addition, the normal hierarchy of CD8+ Tcell 
responses observed in wild type mice appears to be markedly impaired in 
ERAAP-/- mice [225]. The ability of virus to escape from immune detection 
has been observed, in 2004 Draenert et al., first shown that in HLA-B57+ HIV 
infected individuals, a mutation from alanine to proline at position 146 of HIV 
Gag protein alters antigen processing mediated by ERAP1 [226]. The 
variant, positioned immediately before the NH2 terminus of a dominant HLA-
B57 restricted CTL epitope, prevents the N-terminal end cleavage by 
ERAP1. Interestingly, variants in ERAP2 have been shown to confer 
resistance to HIV-1 infection, possibly through an indirect modulation of 
peptide repertoire to CD8+ T cells [121]. Intriguing, ERAP1 is a host target 
of human cytomegalo virus (HCMV) microRNA miR-US4–1 as result of 
miRNA-based immunoevasion strategy.  Interfering with ERAP1, miR-US4–
1 influences the HCMV-derived supply and result in a immunoevasion 
process [203]. 
The most significant risk factor in the pathogenesis of cervical carcinoma is 
the infection with the human papilloma virus (HPV). HPV infects the 
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epidermis and mucous membrane, which consequently causes alterations 
within the cells that leads to cervical neoplasms. SNPs in the ERAP1 gene 
have been described in different cervical carcinoma cases. SNP at 56 and 
127 position give rise to a significant increase in risk of cancer and a 
decrease in overall survival [217]. Loss function studies show ERAP1 as a 
predictor of survival in cervical carcinoma patients [227]. It is plausible that 
polymorphisms within ERAP1, which alternate enzyme activity or specificity 
and consequently peptide generation, facilitate or not the disease 
progression modulating immune response.  
9.3 Autoimmune diseases  
Fierbracci et al., have demonstrated though GWAS the involvement of 
ERAP1 and ERAP2 with the susceptibity to different autoimmune diseases 
and their linkage with particular MHC I alleles [228]. An example is the link, 
demonstrated by different independently replicated studies, between 
ankylosing spondylitis (AS), an autoimmune inflammatory disorder, and 
ERAP1 genetic variants [229-230]. 
The variant K528 has been found in a cohort of HLA-B27-positive AS patients 
and it seemed to have faster trim-activity rate of peptide precursors then wild 
type variant. It suggests an aberrant peptide trimming mediated by ERAP1 
that leads to an impaired peptide presentation mediated by HLA-B27 as 
causes in the AS pathogenesis [231]. Moreover, the mutant variant seems 
to increase susceptibility to multiple sclerosis (MS) based on an Italian 
population study [232]. In a recent genome wide meta-analysis study, 
ERAP2 has been identified to be linked with a risk of developing Crohn’s 
disease [233].  
9.4 Cancer 
As well as screening for SNPs associated with essential hypertension, Mehta 
et al., has verified 13 SNPs within TAP transporters, LMP2, LMP7 and ERAP 
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genes and has described polymorphisms in ERAP1 associated with an 
increased risk in cervical carcinoma development [216; 234]. 
The ERAP1 and ERAP2 expression in several tumour cell lines (such as 
melanomas, leukemia-lymphomas and carcinomas of breast, colon, lung, 
chorion, skin, prostate, cervix, kidney and bladde) reveals a  variation in 
protein expression (down and up regulated) independently from each other 
[235-236]. Following this, Fruci et al., analysed 150 neoplastic lesions and 
found an altered expression of both aminopeptidases (lost, acquired or 
retained) compared to the normal sample [237]. As the expression of ERAP1 
and MHC I molecules are related, as expected, the altered expression of 
ERAP1 results in abnormal cell surface expression of MHC I molecules in 
tumour cell lines [236]. An increase in expression in ERAP1 and/or ERAP2 
proteins has been described in thyroid and colon carcinomas, while a 
downregulation of the same genes has been detected in lung, ovary and 
breast carcinomas [237]. Losses and gains of ERAP1 and ERAP2 protein 
expression were identified in RCC lesions with an altered frequency in 
different renal tumour types [263]. Altered ERAP1 expression has been 
detected in 64% of endometrial carcinomas and, interestingly, this correlated 
with CA-125 levels, suggesting an involvement of the enzyme in tumour 
progression [238]. In addition, analysis of ERAP1 and ERAP2 expression in 
malignant cells has demonstrated that the levels of these enzymes undergo 
significant changes and may correlate with the ability of cancer cells to evade 
immune responses modulating antigen processing. Thereby ERAP 
modulation might be a novel tool that can guide the development of 
innovative approaches to cancer immunotherapy. Interfering with ERAP1 
expression leads to tumour rejection in syngeneic animals by activation NK 
cells, and subsequently T cell-mediated cytolysis. This rejection was mainly 
due to NK cell response and is dependant upon the MHC I peptides 
presented [239-240].  
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Recently, a correlation between tumor suppressor factor p53 and ERAP1 
has been highlighted, suggesting that p53 may be an activator of ERAP1 and 
it could be able to modulate MHC I molecule expression [241], thereby  
playing a crucial role in the regulation of immune responses, specifically in 
several aspects of the cytotoxic T-lymphocyte (CTL)-tumor cell interaction 
[242]. 
9.5 Cytokine Receptor Shedding 
In addition to the role in peptide processing, an involvement of ERAP1 has 
been suggested in the facilitation of interleukin receptor shedding from the 
cell surface, resulting in the soluble form of these receptors. Firstly, Cui et 
al., demonstrated a potential interaction between the extracellular domain of 
the TNFR1 and ERAP, giving rise to the formation of a TNFR1/ERAP1 
complex. In this context, ERAP1 is referred as aminopeptidase regulator 
TNFR shedding 1 (ARTS1) [198]. Overexpressed ERAP1 correlates with an 
increase in soluble TNFR1, which competes with cell surface TNF receptors, 
obtaining an attenuation of TNFα bioactivity when the levels are elevated and 
a rescue of TNFα when the levels have decreased. The data obtained 
suggest an indirect mechanism mediated by ERAP1 in cytokine receptor 
cleavage; this is more consistent due to supporting evidences that suggests 
an involvement of ERAP1 in the recruitment of other enzymes that act as 
endopeptidases or sheddases [200; 243]. In both human and mouse cell 
systems the role of ERAP in IL-6R shedding has been described. 
Subsequently, the same group demonstrated the role of the enzyme in type 
II IL-1 decoy receptor (IL-1RII) cleavage [200;244].  
There are data on ERAP1 variant that can modify the ability of ERAP in 
mechanism of facilitating cytokine receptor cleavage. E320A mutant showed 
an abrogation in facilitate IL-6R shedding, as well R725Q and D575N 
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variants [157]. However, the ability for the SNP variant ERAP1 molecules to 
alter IL-6R ectodomain cleavage is still unclear. 
10. Non-immunological function of ERAP 
ERAP1 controls left ventricular mass through the renin-angiotensin system, 
essential for regulation of blood pressure [246]. This physiological system 
starts with the generation of angiotensin I, derived from cleavage of 
angiotensinogen. Successively angiotensin I is converted to angiotensin II by 
angiotensin converting enzyme (ACE). This last product can control blood 
pressure by modulation of hormone release [222]. Hattori et al., has 
demonstrated an efficient ERAP1 cleavage activity of angiotensin II to 
angiotensin III and IV [245], while Tanioka et al., highlight the ability of 
ERAP2 to cleave angiotensin III to angiotensin IV [195]. Notably, in the same 
study it was demonstrated that both enzymes can convert kallidin to 
bradykinin. 
ERAP1 has been reported to control post-natal physiological process 
involving in growth of new blood vessels from pre-existing microvessels, 
referred to neo-angiogenesis. It occurs because ERAP1 seems to be 
involved in regulation of proliferation and migration events in endothelial cells 
(EC) [246]. Suppression of ERAP1 expression in this EC model inhibited 
VEGF-stimulated proliferation, migration, vessel network formation in vitro, 
and angiogenesis in vivo. It has been showed that ERAP1 can modulate 
VEGF stimulated G1-S transition during EC cell proliferation and it occurs 
binding phosphatidylinositol-dependent kinase 1 (PDK1). The resulting 
complex ERAP1-PDK1-S6 kinase activates cyclin-dependent kinase (CDK) 
4/6 leading to G1/S-phase transition in the cell cycle and EC proliferation 
[247].
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Immune response during HIV-1 infection and replication is quite complex 
because many viral and host factors, beyond individual variables, are 
involved at different levels [85]. Many efforts have been made to evaluate the 
influence of these factors on HIV-1 infection and disease progression, mainly 
focusing on the identification of genetic variants that can play a role in HIV-1 
infection susceptibility.  
ERAP1 and ERAP2 enzymes are involved in antigen presentation, trimming 
the amino-terminus of peptide precursors to the correct size for binding to 
MHC class I molecules. Haplotype-specific alternative splicing of the ERAP2 
gene results in either a spliced (Hap B) or full-length (Hap A) mRNA being 
expressed. Interestingly, the frequency of the latter is higher in HIV-Exposed 
Sero-Negative (HESNs) individuals [121] suggesting that Hap A is involved 
in HIV-infection resistance [122]. 
Based on these premises, the present study strive for deepening the 
correlation between ERAP2 haplotypes and HIV-susceptibility and 
investigating the molecular mechanism by which Hap A and Hap B control 
peptide production for antigen presentation mechanisms and the subsequent 
CD8 mediated immune response. 
In particular, primary aims of this study are: 
 To evaluate the frequency of single and combined SNPs within four 
immune genes (APOBEC3H, TLR3, ERAP2 and MX2), known to be 
“resistance genes” in viral context, in HIV-positive patients receiving 
ART.  
 To identify a possible correlation between the frequency of single 
and/or combined previously mentioned polymorphisms 
(“supergenotype”) and the course of infection in HIV-positive patients 
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receiving ART, using the viral load slope and CD4/CD8 cell count as 
indexes of response to therapy. 
 To confirm and better characterize the correlation between ERAP2 
and HIV-1 susceptibility, by adopting specific experimental conditions 
(recombinant ERAP2 protein and ERAP2 inhibitor addition to cell 
culture). 
 To investigate the trimming phenotype of the two ERAP2 haplotypes 
and to assess their impact on the peptide repertoire and related CD8+ 
T cell immune response. 
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1. Role of ERAP2 variants in HIV1-infected ART-treated 
patients (ICONA Cohort) 
1.1 Sample collection 
300 HIV-infected patients from the ICONA cohort undergoing a first ART 
regimen were enrolled in the study. Blood samples were collected from each 
patient in EDTA Vacutainer® tubes every 6 and 12 months. Immediately after 
collection, peripheral blood mononuclear cells (PBMCs) were isolated and 
stored at -80°C. Successively cells were transferred to the laboratories of the 
University of Milan for genotyping analyses. Periodically (6 months and 1 
year) HIV-infected patients’ clinical parameters (genotype, gender, CD4 cell 
count, viral load, therapies, year of infection, clinical evolution) were analyzed 
and inserted into a predisposed database (NetCare, Healthware Technology 
s.r.l., Salerno). The study was designed and conducted in accordance with 
the Declaration of Helsinki and approved by the Ethics Committee of the 
hospitals involved in the study. After thoroughly explaining the project and 
clarifying any doubt concerning the research, all subjects signed an informed 
consent and the biological material collected was anonymized to ensure the 
privacy of each individual. 
1.2 Genotyping analyses 
DNA was extracted by the Maxwell® RSC Instrument automated following a 
nucleic acid purification method (Promega, Madison, Wisconsin, USA) 
associated with Maxwell® RSC Blood DNA Kit Technical Manual (Promega, 
Madison, Wisconsin, USA). Genomic DNA was used as template for PCR 
amplification using TaqMan probes specifically designed to perform a SNP 
genotyping assay (Applied Biosystems, Foster City, CA, USA). The 
amplification and fluorescence reading were carried out using a Real-time 
PCR instrument (CFX Real Time, Biorad). The determination of the allele 
presence in each sample was done by a specific software (CFX 
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Manager Software, Biorad), which assesses the fluorescent signals 
measured during the plate reading. The list of the gene variants analysed by 
this strategy and the code of the TaqMan assay used are listed in the table 
below:  
 
Table 3.1 List of genetic variants analysed and correspondent code.  *MX2 probe is 
a custom TaqMan SNP genotyping assay. 
Moreover, genomic DNA was used to detect polymorphic 32 bases pair 
deletion at the CCR5 locus using PCR specific custom primers.  
1.3 Statistical analyses 
The allelic discrimination method was used to determine the frequency of 
each genetic variant (SNP). The main characteristics of the study population 
at the time of ART initiation were described and tabulated. Separate models 
were employed to evaluate the association between the detection of the 
genetic variants and HIV-RNA, CD4 count and CD8 count (as well as their 
ratio) responses to ART. For the HIV-RNA response, the time to achieving a 
value ≤50 copies/mL after ART initiation was evaluated by means of standard 
survival analysis and Kaplan-Meier curves. The date of the first HIV-RNA 
value ≤50 copies/mL after ART initiation (a single value) was used to define 
the time of achievement of viral suppression. Participants’ follow-up was 
censored at the date of their last available viral load. For each gene and all 
four endpoints (HIV-RNA, CD4, CD8 and CD4/CD8 ratio) a linear mixed 
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model was used to compare intercept and slopes according to variants 
detection. Variability between patients was controlled using random 
intercepts and slopes. Viral load was fitted in the log10 scale to achieve 
distribution symmetry. Besides testing the associations with each gene 
variant, also a genotypic score was constructed by allocating 1 point every 
time a variant was detected and summing all points per participants (i.e. a 
patient in which ERAP2 rs2549782 G/G was detected as well as rs3775291 
C/T or T/T for TL3 and none of the others would have a value of 2 for the 
score, etc.). In detail, participants were grouped and compared according to 
whether they had a score >3 vs. 0-1. The score is referred as ‘supergenotype’ 
throughout the results of this chapter. All models were fitted on the whole 
dataset of 300 participants and after restricting to 255 participants of 
Caucasian origins. 
2. Role of ERAP2 in vitro HIV-1 infection  
2.1 Sample collection 
Blood samples were collected from 30 HIV-1 seronegative Italian healthy 
controls of Caucasian origin by venepuncture in Vacutainer tubes containing 
EDTA (Ethylene diamine tetra acetic acid) (BD Vacutainer, San Diego, CA). 
All subjects provided written informed consent to participate in this study.  
2.1.1 Isolation of PBMCs 
The separation of PBMCs by whole blood was made on lymphocyte 
separation medium (Lympholyte-H, Cederlane Laboratories, Burlington, NC, 
USA). Briefly, after centrifugation on a Ficoll discontinuous density gradient 
the sample was separated in the following layers from top to bottom: plasma 
and platelets, PBMCs, Ficoll and red blood cells, covered by a granulocyte 
layer. The PBMCs layer was carefully removed from the tube and transferred 
to a new one. After washing with phosphate buffered saline (PBS) buffer, cell 
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number and cellular vitality were determined by ADAM MC Automated 
Mammalian Cell Counter (NanoEnTek Inc).  
2.2 Genotyping 
Automated DNA Purification was performed by Maxwell® RSC Whole Blood 
DNA Kit according to the manufacturer instruction (Promega, Madison, 
Wisconsin, USA). Genomic DNA was used as template for PCR amplification 
using TaqMan specific probes for rs2549782 ERAP2 SNP (G/T) (TaqMan 
SNP Genotyping Assay; Applied Biosystems, Foster City, California, USA). 
Allele analyse was performed by allelic discrimination PCR method on a CFX 
BIORAD Real Time instrument (Biorad) 
2.3 Cell cultures and in vitro HIV-infection 
After isolation, PBMCs were cultured at 37°C and 5% CO2 in RPMI 1640 
(Euroclone) supplemented with 20% Fetal Bovine Serum (FBS). 2x106 
PBMCs isolated from 15 GG (Hap A) and 15 TT (Hap B) healthy donors were 
cultured in RPMI 1640 containing FBS (20%) with or without 100ng/mL of 
recombinant (rh) ERAP2 (R&D) or with or without 100 nM/mL of ERAP2 
inhibitor (DG013A) [248]. After 3 hours, 0.5ng/1x106 cells HIV-1Ba-L virus was 
added to each well and incubated for 24 hours at 37°C and 5% CO2. Cells 
were then washed and re-suspended in medium containing IL-2 
(15ng/ml)(R&D systems, Minneapolis, Minnesota, USA), RPMI 1640 
containing 20% FBS  with/without 100 ng/mL of recombinant ERAP2 FL 
(R&D) or with/ without 100 nM/mL of ERAP2 inhibitor (DG013A) and 
incubated at 37°C and 5% CO2. Every two days cells were supplemented 
with IL-2, recombinant ERAP2 FL or ERAP2 inhibitor. Six days post-infection 
0.5x106 PBMCs were analyzed by FACS for CD8+ T cells mediated 
response. 
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2.4 p24 ELISA 
As index of HIV infection, an HIV-1 p24 Elisa assay kit (XpressBio, Frederick, 
MD, USA) was used to measure viral p24 in PBMC culture supernatants after 
6 days of infection according to the manufacturer’s protocol. Not in detail, 
after plating samples directly into the monoclonal antibody-coated microplate 
wells, the captured antigen is complexed with biotinylated polyclonal 
antibody to HIV-1 p24, followed by a streptavidin-HRP (horseradish 
peroxidase) conjugate. The detection of the resulting complex is been done 
adding ortho- phenylenediamine-HCl (OPD) which produces a yellow colour 
directly proportional to the amount of HIV-1 p24 captured.  Plates were read 
at 450 nm, using the IMark microplate reader equipped with Microplate 
Manager® 6 software (Biorad, Hercules, CA, USA). The absorbance of each 
microplate well was calibrated against the absorbance of an HIV-1 p24 
antigen standard curve. Samples with absorbance values equal to or greater 
than the cut-off factor were considered initially reactive and were retested in 
duplicate to determine whether the reactivity was reproducible. The 
concentration of 1.7 pg/mL is the assay detection’s limit. 
2.5 RNA extraction, DNAse treatment and retrotranscription 
RNA was extracted from basal and cultured PBMCs, using the acid 
guanidium thiocyanate–phenol–chloroform method. After RNAzol addition 
samples were centrifuged at 12,000g for 15 minutes at 4°C and aqueous 
phase, containing RNA, was collected. After isopropanol precipitation and 
75% Ethanol precipitation, pure RNA was extracted and quantified with 
Nanodrop 2000 Spectrophotometer (Thermo Scientific). RNA in RNase-free 
water was purified from genomic DNA with TURBO DNAse (Applied 
Biosystems). One Unit of DNasi and TURBO DNasi buffer was used every 
1µg and the result reaction mix was incubated at 37°C for 30 minutes. After 
inactivation with DNase inactivation reagent (Applied Biosystems), 1 µg RNA 
was reverse transcribed following the manufacturer instructions in a 20-µl 
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final volume by adding 1 µM random hexanucleotide primers and 1 µM oligo. 
The reaction was heated at 70 °C for 5 minutes. Immediately after, dNTPs 
mix, 200 U Moloney murine leukemia virus reverse transcriptase (M-MLV 
RT), 20 U Recombinant RNasi inhibitor and M-MLV 5X reaction buffer were 
added (Promega) and incubated at 42 °C for 60 minutes.  Five minutes 
incubation at 95 °C was used to inactivate the RT. 
2.6 Real Time PCR 
 cDNA quantification for ERAP1, TAP1 and GAPDH was performed by real-
time PCR (DNA Engine Opticon 2; MJ Research, Ramsey, MN). Reactions 
were performed using a SYBR Green PCR mix (Finnzymes, Espoo, Finland). 
This fluorogenic reagent emits a strong fluorescent signal upon binding to 
double-stranded DNA. The thermal profile used was: 15 minutes at 95°C, 
followed by 40 cycles of 15 sec at 95 °C, 1 min at 62 °C and 20 seconds at 
72 °C. By recording the amount of fluorescence emission at each cycle, the 
PCR reaction was monitored and melting curve analysis for amplicon 
identification was performed. Threshold line was set above baseline activity. 
The Ct parameter (Threshold Cycle) is defined as the cycle number at which 
the fluorescence signal passes the fixed threshold. The higher the initial 
amount of genomic DNA, the sooner accumulated product is detected in the 
PCR process, and the lower the Ct value. Ct values ≥ 35 were excluded from 
the analysis. Results were expressed as ΔΔCt and presented as ratio 
between the target gene and the GAPDH housekeeping mRNA. All the 
samples were analysed in triplicate. Table 3.2 shows list of primers used.   
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Table 3.2 List of primers used to assess the expression of genes TAP1, ERAP1 and 
GAPDH. This latter housekeeping is used as a reference for assessing the 
increases. 
 
2.7 Cytofluorimetric analysis  
Flow cytometric analysis was performed at 0 (basal), 4 and 7 days post in 
vitro HIV-1 infection, staining 0.25x106 PBMCs for 15 minutes with 
fluorescent directly labelled antibodies: HLA-ABC FITC, CD8 Pecy7, 
granzymes PE, perforin APC. (Beckman Coulter, CA, USA). As negative 
control, we used cells stained with the appropriate isotype-matched Ig. After 
staining, cells were fixed in 1% paraformaldehyde (PFA, Sigma-Aldrich). The 
expression was detected by mean intensity fluorescence (MFI). Analyses 
were carried out blindly with respect to genotypes. Cytometric analysis was 
performed using a FC500 flow cytometer (Beckman-Coulter CA, USA). Flow 
data were analysed by first gating on the leukocyte population as defined by 
forward and side light scatters and then on CD8+ expression. 
2.8 Statistical analysis 
Statistical analysis were performed using GraphPad Prism analysis software. 
Differences between the groups were assessed using nonparametric 
analyses (Mann–Whitney U test). All P values are two-tailed.  
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3. Trimming function of ERAP2 variants 
3.1 ERAP2 DNA construct generation 
3.1.1 Site Directed Mutagenesis (SDM) 
To generate ERAP2-pcDNA3 DNA constructs with two different stop codons 
in frame, primers were designed for site directed mutagenesis (SDM), which 
utilises a PCR reaction to incorporate a single base change into the template 
DNA. The forward (5’) and reverse (3’) primers for both STOP1 (containing 
stop codon: TAA) and STOP2 (containing stop codon: TAG) consist of 
approximately 20 complementary nucleotide bases either side of the mutated 
nucleotide, and are detailed in Table 3.3. In addition, to generate the correct 
length ERAP2 polymorphism models, primers for STOP 1+9 and STOP 2+9 
were also designed to incorporate 9 additional amino acids into the ERAP2-
FL protein (Table 3.3 and Figure 3.1). To generate these constructs, 50μl 
PCR reaction was set up using KOD Hot Start polymerase and carried out 
according to manufacturers’ instructions, using 5’ and 3’ primers specific for 
the  single base change in the following reaction: 5ul 10x PCR KOD buffer, 
25mM MgSO4, 2mM dNTPs, 10 μM of 5’ and 3’ primers, 1ul KODHot Start 
Polymerase, 0.5 μg DNA template and made up to 50 ul with dH20 (Novagen, 
Merck). The reaction conditions were 95ºC for 2 minutes followed by 18 
cycles of 95ºC x 20 seconds, 65ºC x 10 seconds and 70ºC x 3 minutes. After 
SDM, the product was digested with 1μl Dpn1 (10 units/μl; NEB) for 1 hour 
at 37ºC to digest any methylated adenine residues in the original ERAP2 
DNA template, leaving only mutated ERAP2. DNA was stored at -20°C until 
further use. 
 
 
 
MATERIALS AND METHODS 
 
72 
 
 
 
Table 3.3 Primers for the generation ERAP2 polymorphisms constructs. Primers 
were designed to have a GC content of 55-60% and Tm of 60°C-70°C. Underlined 
and bold base’s change. 
 
 
 
Figure 3.1 Schematic representation for the models construction. 
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 3.1.2 V5-tag 2 step SDM 
Due to the lack of commercial antibodies specific for truncated ERAP2, and 
after analysis of preliminary results, we used a V5 epitope tag sequence at 
the N-terminus of ERAP2 in order to detect in a clearer way the predicted 
protein product for both Hap A and Hap B-derived transcripts. The V5 epitope 
tag is derived from a peptide present at the C terminus of the P and V proteins 
of simian virus 5 (SV5). It contains 14 amino acids: N-GKPIPNPLLGLDST-
C. To add the 14 amino acid tag to all ERAP2 constructs generated as in 
3.1.1, we performed a 2 step SDM reaction, using the first step SDM to add 
the first 7 amino acids (GKPIPNP) and, after a sequencing confirmation, the 
second step SDM added the last 7 amino acids (LLGLDST). The 5’ and 
3’primers were designed to match in N term sequence of ERAP2 in pcDNA3 
plasmid (Table 3.4). The 50μl SDM PCR reaction and thermo-reaction 
conditions were carried out as above (See 3.3.1.1). 
 
Table 3.4 Primers designed to tag plasmids in N terminus with the V5 epitope. 
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3.1.3 Ethanol Precipitation 
To precipitate SDM mutated DNA, the 50ul dpn1 digested SDM product was 
made up to 100μl with dH2O, before the addition of 0.1x 3M sodium acetate 
(pH5.5) and 2.5x 100% ethanol (-20ºC). The DNA was incubated at 37ºC for 
1 hour, and centrifuged at 13,000rpm (4°C) for 20 minutes. The supernatant 
was removed and the DNA washed with 200μl of  70% ethanol (-20°C) by 
centrifuging as above for 5 minutes. The supernatant was removed and the 
DNA pellet left to air dry for 10mins before re-suspending in 10μl H2O. 
3.2 Overlap extension PCR cloning: ERAP2 AS  
In order to create the fully truncated sequence for ERAP2-AS, we used the 
intermediate construct  ERAP2wt + 9aa. Briefly, the alternatively spliced 
ERAP2 mRNA (ERAP2-AS) with an in-frame stop codon results in an  
alternative 27 bases down to the stop codon compared with ERAP2-FL 
(Figure 3.1). To insert these 27 bases (resulting in 9 amino acids) within 
ERAP2 FL sequence, we performed a 2 step overlap extension PCR [249]. 
ERAP2 FL-pcDNA3 (0.5  μg) was amplified using KOD Hot Start polymerase 
(Novagen, USA) and specific primers incorporating the alternative 9 amino 
acids (Table 3.5). The 50ul PCR reactions (1 and 2) were set up as in section 
3.3.1.1 and  PCR cycling conditions as follows: 95°C for 2mins followed by 
35 cycles of 95°C for 20 seconds, 56°C for 10 seconds and 70°C for 32 
seconds for PCR1 and 26 seconds for PCR2. The PCR product from both 
PCR reactions (1 μl) was used as template for PCR 3, with PCR1 5’ and 
PCR2 3’ primers (Table 3.5) used in this reaction. The PCR 3 reaction was 
set up as before and condition followed the manufacturers’ instructions; 95ºC 
for 2 minutes followed by 18 cycles of 95ºC x 20 seconds, 65ºC x 10 seconds 
and 70ºC x 3 minutes. A small sample of PCR product was run on a 1% 
agarose electrophoresis gel to confirm the PCR had been successful and the 
correct size of DNA was present. When successful, the PCR product was 
purified using Qiagen PCR Purification kit (Qiagen, UK) according to 
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manufacturers’ instructions and eluted in 30μl H2O. The amount and 
concentration of DNA present were determined using spectrophotometer 
nanodrop (Thermo Scientific). 
 
Table 3.5 Primers used for intermediate sequence ERAP2wt + 9aa. 
 
3.2.1 Restriction enzyme digestion 
The pcDNA3 plasmid construct and PCR3 product were digested in standard 
30μl reactions consisting of dH2O, 1x BSA, 1x buffer, 3μg DNA, 1μl Hind III 
(12 units/μl; Promega) and 1μl Xho1 (10units/μl; Promega) for ERAP2wt + 
9aa (intermediate of ERAP AS). As negative control, a single restriction 
digest were carried out in 20ul reaction volumes; 10ul dH2O, 1x BSA, 1x 
buffer, 3μg DNA and 1μl restriction enzyme Xho1. Both single and double 
restriction digest reactions were incubated at 37ºC for one hour before being 
run on 1% agarose electrophoresis gel. The DNA was excised from the gel 
and purified according to the QIAquick Gel Extraction kit (Qiagen) following 
manufacturers instructions. 
3.2.2 DNA ligation 
A ligation between HindIII and XhoI digested PCR3 product (ERAP2wt + 
9aa) and pcDNA3 vector was carried out using a molar ratio of 3:1 of DNA 
to vector. T4 DNA ligase (NEB, UK) and 10X ligase buffer were used for 
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ligation in a final reaction of 15μl. The reaction was incubated overnight at 
16°C.  
3.3 Cloning of DNA constructs 
3.3.1 Bacterial transformation 
JM109 competent cells  were used to transform construct DNA generated by 
site directed mutagenesis (See 3.1.1, 3.1.2 ) and TOP10 bacteria (Invitrogen) 
used to transform cloned ERAP2 (See 3.3.2). One ul SDM product or 5μl of 
ligated plasmid DNA was added to 50ul bacterial cells and incubated for 30 
minutes on ice. After this time, the bacteria were heat shocked  at 42°C for 
35 seconds  and placed back on ice before the addition of 250μl SOC media 
(Table 3.6). The bacterial culture was incubated for 1 hour at 37°C with 
shaking at 220rpm before spreading 30 𝜇 l on agar plates containing 
ampicillin (100μg/ml) and incubated overnight at 37 °C. 
 
Table 3.6 Components of LB and SOC medium. 
 
3.3.2 Screening of bacterial colonies 
To screen the bacterial colonies, a selection of colonies were picked 
incubated in 2 ml LB medium containing ampicillin (100μg/ml) at 37°C with 
220rpm shaking for 16 hours. Plasmid DNA was purified from bacteria using 
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QIAprep Spin Miniprep Kit (Qiagen) following the manufacturers’ 
instructions. To determine the successful incorporation of addition or mutated 
nucleotides within the gene sequence, 100 ng/ 𝜇l (10 𝜇l) of miniprep plasmid 
DNA product was sent for sequence verification using Source BioScience 
LifeSciences laboratories (Nottingham, UK). Sequencing primers used are 
shown in Table 3.7.  
 
Table 3.7 Primers used for sequencing. 
 
3.3.3 Maxiprep 
The bacterial culture containing the correct DNA sequences was amplified 
overnight in 150ml LB medium containing ampicillin (100μg/ml) at 37°C with 
220rpm shaking. The QIAfilter Plasmid Midi and Maxi kit (Qiagen) was used 
to purify a greater quantity of plasmid DNA for use in functional assays, 
resuspending DNA in TE buffer before determining the concentration of 
purified DNA using the Nanodrop. 
3.4 Cell based functional assessment of ERAP2 constructs 
3.4.1 Cell culture and maintenance 
293T ERAP1-ERAP2 -/- cells were maintained at 37°C/5% CO2 in DMEM 
culture medium (Sigma) and B3Z T cell hybridoma (Nilabh Shastri, University 
of Berkeley, California) maintained in RPMI 1640 culture medium (without 
glutamine, Lonza, UK). Both the media (RPMI 1640 and DMEM) were 
supplemented with 10% heat inactivated (56 °C for 30min) fetal bovine serum 
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(FBS, PAA, UK), 2mM L-glutamine (Lonza, UK), 50U/ml Streptomycin 
(Lonza, UK), 50U/ml Penicillin (Lonza, UK), 1% Hepes (1M, PAA, UK).  RPMI 
medium was also supplemented with 500nM β2-mercaptoethanol (Sigma). 
Adherent cell lines were harvested using 1mM EDTA and removed from the 
cell culture vessel by pastette. 
 3.4.2 Transfection of variant model constructs for ERAP2  
Genetic model constructs were introduced into cells using Fugene6 
transfection reagents (Promega, UK). 293T ERAP1-ERAP2 -/- cells were 
seeded at a concentration of 105 cells/ml in 2ml DMEM per well of a six well 
cell culture plate and incubated overnight to achieve 50-80% confluency on 
day 2. Transfection of cells was carried out as follows: 97 μl of serum free 
RPMI was added to 1.5ml eppendorf tubes followed by Fugene6 at ratio 3:1 
with plasmid (3μl Fugene 6 to every 1μg plasmid DNA) and incubated for 5 
minutes at room temperature. After this, 1μg of the plasmid DNA constructs 
were added (DNA per reaction described in Table 3.8) and incubated at room 
temperature for 15 minutes. After the incubation, the transfection mix was 
added drop wise to cells and maintained at 37°C/5% CO2. At the time points 
of 24 and 48 hours, 1x106 cells and cellular supernatants were harvested for 
subsequent protein analyses. 
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Table 3.8 List of plasmid used during transfection assay. H-2kb is a molecule of 
MHC class I complex requested for antigen presentation. R-SHL8 and SHL8 are 
peptides, the first needs to be cleaved before be presented instead the SHL8 is ready 
to be loaded to the antigen presentation complex (used as positive control for the 
assay).  
 
3.4.3 T cell activation assay 
After 24hours transfection, 293T ERAP1-ERAP2 -/- cells were harvested, 
counted and 2x105 cells added into the first well of a 96 well plate. The cells 
were titrated, to achieve a 1:2 dilution across the plate, with 1x105 cells in 
100ul the starting well.  The LacZ inducible B3Z T cell hybridoma were 
counted and added to the 293T ERAP1-ERAP2 -/- at 105 cells/100μl per well. 
After co-culture overnight incubation at 37°C, plates were centrifuged at 
1500rpm for 2 minutes, the supernatant discarded and replaced with 100μl 
per well of chlorophenol red-beta-D-galactopyranoside (CPRG; 91mg 
CPRG, Roche) and incubated at room temperature. CPRG is a substrate for 
β-galactosidase and the response is generated through the activation of T 
cells by the recognition of SHL8 peptide in complex with the H-2Kb which 
transcribes the LacZ reporter gene generating β- galactosidase. In the 
presence of β-galactosidase, CPRG is cleaved releasing a substrate causing 
colour change from yellow to increasing intensities of red upon cleavage. 
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This colour change direct relates to the number of SHL8-H-2Kb complexes 
at the cell surface and is determined by a Biorad 680 microplate reader. 
Readings were taken every hour at a reference wavelength of A595nm with 
an additional wavelength of A695nm used to subtract background levels from 
the result. The data was then analysed using GraphPad Prism software. 
Statistical analysis was undertaken using an unpaired T test with 99% 
confidence interval, or with one-way ANOVA with Welch correction with a 
99% confidence interval. 
3.5 Molecular Biology 
3.5.1 Cellular Supernatants concentration  
During the transfection assays, at 24 and 48 hours cellular supernatants 
were collected for protein analyses. To concentrate the extracellular proteins 
within supernatants, Amicon Ultra15 centrifugal filters 30K (Millipore) were 
used to centrifuge samples (2ml) for 30 minutes at 2500 rpm (4 °C). After this 
step, the concentrated supernatant (~200 μl. 10X) was collected and 
transferred to an eppendorf for subsequent protein analyses. 
3.5.2 Immunoprecipitation (IP) for V5 tag  
To reduce the non-specific binding and improve the detection of ERAP2 
protein from the supernatants, immunoprecipitation assay of V5-tag 
transfected supernatants was performed after the concentration step above. 
Dynabeads protein G (Invitrogen, UK) were resuspended in solution and 50μl 
was transferred to a tube, placed on the supplied magnet to separate the 
beads from the solution, and the supernatant discarded to leave only the 
magnetic dynabeads. Five μg of V5 antibody (ThermoFisher) was diluted in 
200 μl PBS and added to the beads, incubating with rotation at room 
temperature for 10 minutes in order to bind the antibody to the dynabeads 
via the Fc region of the antibody. The beads-antibody complexes were 
placed on the magnet and the supernatant removed. 200 μl of concentrated 
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supernatant (See 3.5.1) was mixed with antibody-bead complex and 
incubated with rotation at room temperature for 10 minutes to allow the bond 
antibody-target protein complex. The tubes were placed on the magnet and 
the supernatant removed and retained for further analysis. The dynabeads-
antibody-protein complex was washed three times in 200μl PBS 0.1% Tween 
for each wash step.  Finally the complex was re-suspended in 100μl PBS 
0.1% Tween and transferred into a clean tube to avoid co-elution of proteins 
bound to the tube wall. To elute the target proteins, the complexes were 
mixed with 20μl 1x NRSB, gently re-suspended by pipetting, and heated for 
10 minutes at 70°C to dissociate the dynabead complex. After heating, the 
sample was placed on the magnet and the supernatant remaining was used 
to analyse by immunoblotting. 
3.5.3 Immunoblotting 
3.5.3.1 Preparation of cell lysates 
To create protein lysates from cells after 24 and 48 hours after transfection, 
2x106 cells (previously counted) were centrifuged at 1200rpm for 5 minutes 
and washed in 500μl PBS and transferred to an eppendorf and centrifuged 
at 2,000rpm for a further 3 minutes, in order to generate a pellet of cells. The 
PBS was discarded, and the pellet of cells re-suspended in NP40 lysis buffer; 
150mM NaCl (Sigma), 5mM EDTA (Fisher), 20mM Tris-HCl pH7.4 (Sigma) 
and 1% Nonidet-P40 (NP40, US Biological, USA). Protease inhibitors 
iodoacetamide (IAA, 5%, Sigma) and phenylmethyl sulfonyl fluoride (PMSF, 
5%, Sigma) were added to the lysis buffer. After 30 minutes of incubation on 
ice, the tubes were centrifuged at 13,000rpm for 20 minutes at 4°C to pellet 
the unwanted cell debris. The resulting supernatant was collected and stored 
at -20°C until required. 
MATERIALS AND METHODS 
 
82 
 
3.5.3.2 SDS-PAGE gel 
Protein lysates were separated on a 10% SDS-PAGE gel, consisting of 10% 
resolving gel followed by 5% stacking gel for loading of protein samples 
(Table 3.9). 3x Non reducing sample buffer containing 50% glycerol, 1M Tris 
pH 6, 10% SDS and H2O, was added to each sample (protein extracts and 
supernatants) and loaded onto the gel, along with 1ul Magic Marker (Sigma) 
and 3μl Pro sieve marker (Invitrogen). After 1 hour of run in 1X SDS running 
buffer at 200V, the proteins were transferred from resolving gel to a 
nitrocellulose membrane hybond C (Amersham, UK) at 23V for 1 hour at 
room temperature. Layers of sponges, paper, hybond C, resolving gel, paper 
and sponges were assembled. 5x transfer buffer (72.05g glycine, 15.15g Tris 
base made to 1litre with H2O) diluted to 1x using 50ml 5x transfer buffer, 
150ml H2O and 50ml ethanol, were added to the tank.  
 
 
Table 3.9 Contents of the resolving and stacking gels for Western Blot analysis. 
 
3.5.3.3 Blocking and immunodetection 
To block non-specific binding sites the nitrocellulose membrane was 
incubated, in agitation, at 4°C overnight in blocking buffer (5% milk (Marvel) 
in PBS with 0.1% Tween 20 ,Sigma). The membranes were washed (3x 10 
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minutes) with 10ml fresh wash buffer (PBS with 0.1% tween 20). Primary 
antibody was added and incubated for 1 hour at room temperature, followed 
by 3x 10 minutes washes before 1 hour of incubation in secondary antibody.  
Before the detection, furthermore 3 washes have been made. The primary 
and secondary antibodies were diluted in blocking buffer (5% milk in PBS 
0.1% Tween 20) (Table 3.10). In order to detect the presence of proteins, the 
membrane was developed using equal volumes of super signal enhancer 
and super signal stable peroxide (ThermoScience) were mixed and 
incubated for 5 minutes on the membrane then exposed and imaged with 
Fluor-S Multi-imager (Biorad, UK). 
 
Table 3.10 Antibodies used in immunodetection (WB) and IP. 
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1. Role of ERAP2 variants in HIV1-infected treated 
patients (ICONA Cohort) 
1.1 Clinical parameter analysis of the ICONA cohort subjects 
Studies on HESNs carried out in collaboration with the Infectious Diseases 
Unit of SM Annunziata Hospital in Florence, have led us to the definition of a 
group of genes (TLR3, MX2, APOBEC3H and ERAP2) whose haplotypes 
are related to the immunologic advantage of these subjects. Nevertheless, it 
is not yet known whether the combination of protective gene variants may 
correlate to different responses to therapy in HIV-positive subjects 
undergoing ART. For all these reasons, 300 HIV-infected patients from 
ICONA cohort undergoing a first ART regimen were enrolled in this study 
with the aim of evaluating the frequency of single and combined SNPs within 
the four previously mentioned genes. In addition, we investigated a possible 
correlation between the frequency of single and combined polymorphisms 
(“supergenotype”) and the course of infection in HIV-positive patients 
receiving ART, using the viral load slope and CD4+ cell count as indexes of 
response to therapy.  
Demographic and clinical parameters of enrolled subjects are summarised 
in Table 4.1, in which age, gender, mode of HIV transmission, AIDS 
diagnosis, presence of coinfections, CD4+/CD8+ cell counts and viral load 
are reported. 
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Table 4.1 Clinical and demographic characteristics of HIV-infected patients enrolled 
in the ICONA cohort. 
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1.2 Analysis of allelic variants in the ICONA cohort 
The ICONA cohort genotyping results and the prevalence of different 
polymorphisms in our immune genes patients are summarised in Table 4.2. 
No differences in SNP frequency between HIV-infected cohort and both 
World and European population were observed. In addition, the co-presence 
of single and combined polymorphisms previously mentioned is reported in 
Table 4.3. The analysis did not show any significant result in terms of 
prevalence of genetic variant combinations in the enrolled individuals. 
 
Table 4.2 Genotyping results of prevalence and frequency in subjects of the ICONA 
cohort. Protective SNPs are underlined.  
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Table 4.3 Number/Sum of protective alleles in subjects of the ICONA cohort. 
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1.3 Correlation between single allelic variants and clinical 
parameters (CD4+/CD8+ T cell count and Viral Load) 
One of the aims of the project was to explore whether there was a correlation 
between protective gene variants and a different response to therapy in HIV-
positive subjects undergoing a first regimen of combination antiretroviral 
therapy (cART). As expected, we did not find any association between the 
analysed allelic variants and the clinical characteristics of HIV-infected 
patients enrolled at baseline time-point (data not shown). Similarly, no 
association between allelic variants within APOBEC3H, TLR3 and MX2 
genes or HIV viral load and CD4+ /CD8 + T cell count slopes was observed 
in our cohort 12-months post cART administration (data not shown). 
Conversely, we observed a significant association between the frequency of 
the GG allelic variant of ERAP2 and response to therapy. Indeed, for 
rs2549782 G/T there is evidence that the GG genotype (protective form) is 
associated with a steeper decline in HIV-1 viral load after adjusting for age, 
gender, CD4+/CD8+ T cell count and VL at cART, use of INSTI or >3 drugs, 
ART-naive and year of starting cART Figure 4.1).   
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Figure 4.1 Mean intercept and slope of log10 Viral Load (A), CD4+ T Cells (B) and CD8+ T cells (C) from fitting a mixed-linear 
model in ICONA subjects. Panel D shows the ratio of CD4/CD8 in ICONA subjects. All the data are adjusted for age, gender, ratio 
and VL at cART , use of INSTI or >3 drugs, ART-naive and year of starting cART. 
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Notably, the association with a steeper decline in HIV-1 viral load is even 
stronger (p=0.042) when the analysis is restricted to people of Caucasian 
ethnicity (251 subjects) (Figure 4.2 A). Patients carrying this genotype also 
show a trend towards a steeper increase in CD4+ T cell count (Figure 4.2 B). 
As for CD8+ data in GG patients, we observed no differences in CD8+ T cell 
count over 1 year-treatment.  Conversely, TT/GT genotyped patients show a 
decrease of CD8+ T cell count over the year (Figure 4.2 C). This results in a 
significant association with a steeper decline in CD8+ T cells in TT/GT 
patients but it could be explained by a no difference in change/year in CD8+ 
T cell count over time in GG patients. Further analyses concerning this 
aspect are not possible in this observational study, however these data 
support the necessity to deepen the role of this rs2549782 G/T allelic variant 
in a case/control study. Nevertheless, no differences in CD4+/CD8+ cell ratio 
have been observed over time in our cohort after controlling for age, gender, 
CD4+/CD8+ T cell count and VL at cART, use of INSTI or >3 drugs, ART-
naive and year of cART start (Figure 4.2D). These results are particularly 
relevant considering the key role played by ERAP2 in the orchestration of the 
immune system. Indeed by trimming the N-terminal end of peptide loaded on 
MHC class I molecules, it is able to shape the CD8+ T cell repertoire that 
controls viral replication. Therefore, it is possible to speculate that peptides 
generated by homozygous G subjects are qualitatively and/or quantitatively 
more protective against viral replication and this hypothesized difference in 
antigen processing could have a role in terms of a better response to ART 
treatment in HIV+ patients. 
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Figure 4.2 Mean intercept and slope of log10 Viral Load (A), CD4+ T Cells (B) and CD8+ T cells (C) from fitting a mixed-linear model 
in Caucasian ICONA subjects. Panel D shows the ratio of CD4/CD8 cells in Caucasian ICONA subjects. All the data are adjusted for 
age, gender, ratio and VL at cART , use of INSTI or >3 drugs, ART-naive and year of starting cART.
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1.4 Correlation between combined allelic variants and clinical 
parameters (CD4+ or CD8+ T cell count and Viral Load) 
One of the aims of this study was to identify combinations of polymorphisms 
(a “supergenotype”) in genes that are considered to be protective in viral 
infection / replication control and response to ART therapy by monitoring the 
clinical parameters of interest (VL and CD4/CD8 lymphocyte counts). 
Specifically, a score (SNP score) is assigned to each SNP variant (Table 4.3 
A) and all the subjects are grouped following the score assigned (Table 4.3 
B). With the latter, we performed a statistical analysis in order to identify a 
combination of variants that could provide an immunological benefit in terms 
of infection and response to therapy. The analysis, however, did not show 
any significant correlation between variant combinations and viral load or 
CD4+ or CD8+ cell counts in either all subjects or just Caucasian subjects of 
ICONA cohort (Figure 4.3). This result was not unexpected because during 
single variant analyses, only the ERAP2 related variant correlated with a 
better response to ART treatment in terms of VL and CD4+ cell count. 
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Table 4.3 SNP score assigned to each variant (A) and frequency-percent of 
Caucasian subjects related to the score (B). 
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Figure 4.3 Mean intercept and slope of log10 Viral Load (A-B), CD4+ T Cells (C) and CD8+ T cells (D) from fitting a mixed-
linear model in Caucasian ICONA subjects. All the data are adjusted for age, gender, ratio and VL at cART , use of INSTI 
or >3 drugs, ART-naive and year of starting cART. 
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2. Role of ERAP2 in in vitro HIV-1 infection 
Interestingly ERAP2 Hap A has been found to be significantly overexpressed 
in HIV-1-exposed seronegative individuals (HESNs), following a recessive 
model and it also correlates with resistance to HIV-1 infection [122]. Results 
obtained above show an involvement of ERAP2 in HIV-1-progression, 
modulating the response to therapy in patients undergoing a first HAART 
regimen. The aim of this part of project was to better characterize ERAP2 
role in HIV-1infection resistance.  
2.1 ERAP2 Inhibition increases susceptibility to in vitro HIV-1 infection  
To confirm the involvement of ERAP2 in HIV-1 susceptibility, PBMCs isolated 
from 30 healthy donors, genotyped for ERAP2 allelic variants, were in vitro 
infected, with an R5 tropic HIV-1 strain. Cell cultures were made in the 
presence or absence of DG013A phosphinic peptide, which is able to bind to 
the ERAP2 catalytic site and inhibit enzyme activity [248]. Notably, under 
basal conditions, cytofluorimetric analysis showed a significant reduction in 
MHC class I (HLA-A, B,C) in Hap B genotype samples compared to the Hap 
A samples (p<0.05) (Figure 4.4). This data indicates a correlation between 
the Hap A genotype and the generation of a greater abundance of HLA-
binding peptides that are presented at the cell surface. This result is further 
supported by experiments showing a correlation between transient knock-
down of ERAP2 with a reduction in cell surface MHC class I expression [137].   
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Figure 4.4 Human leukocyte antigen (HLA)-ABC mean ﬂuorescence intensities in 
HapA and Hap B donor cells at baseline. Mean values and standard error are shown. 
*P<0.05 
Six days after infection, p24 levels were lower in cells from Hap A compared 
to Hap B individuals, a result suggestive of a more general restrictive role of 
ERAP2 in HIV (and likely other) infection. Addition of DG013A caused a 
dose-dependent increase in HIV-1 infection susceptibility, resulting in higher 
p24 levels, in both the haplotypes (Figure 4.5). Unfortunately, when the 
cohort was increased (20 more subjects), we were unable to confirm the 
result obtained. A possible explanation for these opposing results may be 
due to the newly synthesised DG013A, used in the latter experiments, 
showing lower activity and specificity. Therefore, further analyses are 
required to confirm the consequences of ERAP2 inhibition by DG013A 
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Figure 4.5 p24 concentration in PBMCs of subjects with different ERAP2 diplotype 
6 days after HIV-infection in presence/absence of DG013A peptide inhibitor at 
different concentrations (10nM, 100nM and 1000nM). Mean values and standard 
error are shown. 
Four days post in vitro HIV-1 infection in the presence of DG013A, we 
observed an increased mRNA expression of  ERAP1 (GG: p<0.05; TT 
p<0.01 ) and TAP1 (GG: p< 0.005 ;TT: p< 0.05), two further genes involved 
in antigen presentation with a peak effect at 1000nM (Figure 4.6). This result 
could be explained by compensation mechanisms occurring within cells; 
indeed trying to maintain a canonical rate in antigen presentation, in a 
condition where ERAP2 is inhibited, it is plausible to hypothesize an 
enhanced activation in other aminopeptidases and transporter expression, 
such as ERAP1 and TAP1. 
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Figure 4.6 mRNA expression of transporter associated with antigen processing 1 
(TAP1) and endoplasmic reticulum aminopeptidase type 1 (ERAP1) 4 days post HIV-
1-infection in presence or absence of 100nM or 1000nM of DG013A peptide inhibitor. 
Mean values and standard error are shown. * P<0.05, * P<0.01, *** P<0.005.  
 
RESULTS 
100 
 
2.2 rhERAP2 addition in the extracellular milieu reduces viral 
infection and/or replication 
Secretion of ERAP1 and ERAP2 from plasma membrane in response to 
activation has been recently reported [212-214]. We therefore decided to 
investigate if, once released, ERAP2 still retains its antiviral function. PBMCs 
isolated from 30 healthy donors were in vitro infected with an R5 tropic HIV-
1 strain in presence or absence of recombinant (rh) ERAP2 (100 ng/ml). 
Addition of rhERAP2 to cells did not affect cell viability during HIV infection. 
As previously shown, 6 days post in vitro infection, Hap A subjects were less 
susceptible to HIV-1. Notably the addition of rhERAP2 to cell cultures 
resulted in a reduction of viral replication in both Hap A and Hap B individuals 
(Figure 4.7). These differences reached statistical significance when the 
analyses were performed independently of the ERAP2 genotype, (p<0.01) 
(Figure 4.8). Furthermore, this protective effect was independent of 
modulation of HLA-ABC and/or perforin and granzyme expression by CD8+ 
T lymphocytes (data not shown). The role and the targets of ERAP2 in the 
extracellular milieu are still unknown and needs further investigation. 
However, data herein suggests that once added to cell culture, ERAP2 
provides a protective function against HIV-1 infection and, presumably, this 
defensive feature is mediated through an unconventional mechanism, 
distinct from immune system modulation. 
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Figure 4.7 p24 concentration in PBMCs of subjects with different ERAP2 diplotype 
6 days post in vitro HIV-1 infection in presence/absence of 100 ng/ml of 
recombinant (rh) ERAP2.  Mean values and standard error are shown. 
 
Figure 4.8 p24 concentration in 6-day post in vitro HIV-1 infected PBMCs of Hap A plus Hap 
B subjects in presence or absence of 100 ng/ml of recombinant (rh) ERAP2.  Mean values 
and standard error are shown. **p <0.01. 
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3. Trimming function of ERAP2 variants 
The aim of this last part of the project was to investigate and clarify the 
different trimming phenotypes of the two haplotypes, to provide a greater 
understanding of the molecular mechanism underpinning the observation of 
HIV infection susceptibility phenotype mediated by the two haplotypes.   
3.1 Hap B models show a reduced trimming activity compared 
to ERAP2 wt (Hap A) 
To investigate the trimming activity of ERAP2 haplotypes,  ERAP1-ERAP2-
/- 293T cells were transiently transfected with different DNA constructs 
containing either Hap A or Hap B ERAP2 (See 3.1 and 3.2). At the same 
time, cells were transfected with minigenes containing a specific ERAP2 
substrate R-SIINFEHL (R-SHL8) and the relevant MHC class I molecule (H-
2Kb). As a positive control, a minigene containing SIINFEHL (SHL8) final 
peptide was used. This peptide does not require ERAP2 trimming to be 
loaded onto and presented at the cell surface by H-2Kb. By comparison, the 
R-SHL8 peptide requires trimming of the N-terminal Arg amino acid to be 
presented. To detect the generation of the final 8mer SHL8 peptide and the 
subsequent formation of SHL8/H-2Kb complex, we used the B3Z T cell 
hybridoma. These cells express a specific TCR at the cell surface that 
recognises the modified peptide SIINFEHL (original SIINFEKL), bound and 
presented on H-2Kb molecule. Recognition of SHL8-H-2Kb complex by the 
TCR receptor at the cell surface of B3Z, allows the transcription of a β-
galactosidase (lacZ) reporter gene construct in the cells. To detect the 
presence of β-galactosidase, a colorimetric substrate called chlorophenol red 
β-galactopyrannoside (CPRG) is used resulting in a colour change upon 
production of β-galactosidase. This colour change reaction is an indirect 
method to measure the lacZ activity of B3Z cells and directly correlates with 
the amount of SHL8 peptide presented by H-2Kb at the cell surface and, 
consequently, can determine the level of N-terminal processing. As 
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described above, the SHL8 minigene is used as a positive control and an R-
SHL8 minigene transfected together with an empty pcDNA3 vector (no 
ERAP2) is used as the negative control for the assay. Transfection of 
ERAP1-ERAP2-/- cells with ERAP2 haplotypes showed that all the models 
for Hap B ERAP2 have a reduced trimming function compared to the full 
length Hap A ERAP2 (Figure 4.9).   
 
Figure 4.9 Trimming activity assay in ERAP1/2 deficient cells. ERAP1/2-deficient 
293T cells were transfected with Hap A or Hap B ERAP2 together with an N-
terminally extended R-SHL8 minigene and assayed for trimming by the stimulation 
of the LacZ-inducible, SHL8/Kb-specific B3Z T cell hybridoma. As a control for ERAP 
trimming, ERAP1/2 deficient cells were transfected with SHL8 only (+ ctl) and as 
control for the assay cells were transfected with empty pcDNA3 vector and R-SHL8 
minigene (- ctl). Hap A is designated for ERAP2 wt, whereas remaining models 
(stop1, stop1+9, stop2, stop2+9 and E2wt+9aa) refer to Hap B variant of ERAP2. 
 
There are no commercially available antibodies specific for ERAP2-AS, 
therefore in order to confirm the presence of ERAP2 protein in transfected 
cells, we created N-terminally V5 tagged Hap A and Hap B constructs. Figure 
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4.10 shows the comparison of trimming activity between the DNA constructs 
with or without N-terminal V5 tag.  As expected, we did not observe any 
differences in the trimming activity between the two groups of DNA 
constructs, because the N-terminal sequence portion of the ERAP2 gene is 
not related to the aminopeptidase activity of the protein [207]. This result is 
also important for future detection studies, because the V5 tag construct 
allows the detection of predicted protein products for both Hap A and Hap B-
derived transcripts in a clearer way.  
 
Figure 4.10 Trimming activity assay to compare DNA constructs models with or 
without the V5tag. ERAP1/2-deficient cells were transfected with Hap A or Hap B 
ERAP2 together with an N-terminally extended R-SHL8 minigene and assayed for 
trimming by the stimulation of the LacZ-inducible, SHL8/Kb-specific B3Z T cell 
hybridoma. As a control for ERAP trimming ERAP1/2 deficient cells were transfected 
with SHL8 only (+ ctl) and as control for the assay cells were transfected with empty 
pcDNA3 vector and R-SHL8 minigene (- ctl). ERAP2 wt and V5 ERAP2 wt refer to 
Hap A ERAP2; remaining datasets (stop2, V5 stop2, stop1+9, V5 stop1+9, V5 
E2wt+9aa and V5 E2wt+9aa) refer to Hap B. 
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3.2 The different trimming activity of Hap A and Hap B results in 
a different T cell response 
The generation of peptides to present onto MHC I molecules is fundamental 
for recognition and activation of the CD8+ T cell response and the 
subsequent immune surveillance process. Our transfection results revealed 
a significant reduction (p<0.005) in percentage of T cell response (B3Z) in 
Hap B constructs compared to the ERAP2 FL (Hap A) (Figure 4.11 A). The 
same result was also observed with the N-terminal V5 tag constructs 
(p<0.01; p<0.05) (Figure 4.11 B). These results are interesting since the 
difference in trimming activity may help explain the different haplotype-
mediated phenotype in HIV infection. Indeed, it was observed that Hap A 
expression was higher in HESNs [121], subjects who remain seronegative 
despite repeated exposures to the virus, and therefore a greater ability to 
induce and activate a T cell response by Hap A ERAP2  may contribute to a 
natural resistance to infection. Moreover, our results obtained in in vitro HIV 
infection, where GG (Hap A) PBMCs presented a reduction of p24 level (HIV 
replication index) compared with TT genotype (Hap B), agrees with a 
qualitatively and/or quantitatively different peptide repertoire generated by 
the two haplotypes. 
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Figure 4.11 Percentage of T cell response (B3Z) using DNA constructs for Hap B 
compared to the ERAP2 FL wt (Hap A). Panel A shows the reduction of T response 
using DNA constructs without V5-tag, whereas B shows the comparison in T cell 
activation between vectors with and without N-terminal V5 tag. Mean values and 
standard error are shown. *P<0.05, **P<0.005, ***P<0.001. 
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3.3 ERAP2 localization (preliminary results) 
Evidence that ERAP1 and ERAP2 play a fundamental role in ER proteolysis 
and the subsequent ER localisation are well established. However, recently, 
the subcellular localisation of the two aminopeptidases has been questioned 
[194-195]. To investigate the localisation of the derived protein for both Hap 
A and Hap B transcripts, we collected 2x106 cells and supernatants from cell 
cultures used in trimming activity assays, at 24 and 48 hours after 
transfection. Cells that had been transfected with ERAP2 FL showed the 
presence of a clear full-length ERAP2 protein band (120 kDa) in Hap A model 
samples at 24 and 48 hours post transfection. In Hap B samples, weak 
signals at 120 and 60 kDa (size of predicted truncated ERAP2 protein) have 
been detected at 24 hours (Figure 4.12 A). By contrast, protein analysis 
performed on cell lysates derived from V5 tag transfections did not show the 
60 KDa band, whereas the 120kDa ERAP2-specific V5 signal was detected 
in both Hap A and Hap B (Figure 4.12 B ). This result suggests that protein 
translation run through leading to a full-length ERAP2 protein even in 
constructs that possess a stop codon. Interesting, the result is consistent with 
the trimming data (see 3.1), with greater trimming activity observed in Hap A 
transfectants and a clear 120 kDa band in lysates. Whereas in Hap B models, 
a very low ERAP2FL signal is consistent with the reduced (almost zero) 
trimming activity. 
 
 
 
 
 
 
RESULTS 
108 
 
 
Figure 4.12 WB on cell lysates from transfected cells with pcDNA3 constructs (A) 
and V5 tag constructs (B).  In A protein analysis shows the presence of a clear FL 
ERAP2 protein (120 KDa) in Hap A samples (indicated by red arrow), whereas weak 
signals at 120 and 60 kDa (predicted truncated ERAP2 protein HapB-derived; 
indicated by green arrow) are detected in Hap B samples at 24 hours post 
transfection. The 60kDa signal is lost in V5 blot (B) whereas a specific V5 signal at 
120 kDa is still detectable. – ctl (cell lysis without V5 tag) is used as negative control. 
 
An extracellular localisation of ERAP1 has been previously described by 
several studies, more recently data about extracellular ERAP2 has been 
published [212-214]. For this reason, we decided to analyse the protein 
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content also in cellular transfection supernatants, however analyses did not 
detect any ERAP2 protein (data not shown). However, this result is not 
unexpected since the secretion of ERAP1 and ERAP2 are related to a 
stimulation condition with LPS and IFNγ [212-213], stimuli not introduced in 
these experiments. Future analyses will be performed to characterise both 
ERAP2 FL and ERAP2 AS and whether they are secreted. 
These protein data, even if not completely defined, are consistent because 
they suggest a possible presence of a skip-stop codon mechanism in Hap B, 
derived from the detection of an ERAP2 FL signal in V5 in cells transfected 
with Hap B ERAP2. These data contradict the assumption that ERAP2-AS 
(Hap B) mRNA undergoes a non-sense-mediated decay [120], however 
previous transfection experiments performed in our laboratory suggest Hap 
B mRNA might be translated [250]. Interesting this plausible skip-stop codon 
process could explain the intermediate frequency of the haplotype in most 
human populations. Moreover, future specific experiments will investigate 
the function and localization of the predicted protein products of Hap A/Hap 
B-derived transcripts and assess their impact on infection of cells with HIV. 
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The immune response during HIV-1 infection and replication is quite complex 
because many viral and host factors, beyond individual variables, are 
involved at different levels [85]. Many efforts have been made to evaluate the 
influence of these factors on HIV-1 infection and disease progression, 
focusing mainly on the identification of genetic variants that can play a role 
in HIV-1 infection susceptibility. These studies have led to the concept of 
"immunological advantage", which would confer resistance to HIV to those 
individuals who possess it. The best prototype of such condition is 
represented by HIV exposed seronegative (HESN) subjects, whose 
phenotype has been consistently associated with a number of genetic 
correlates protecting them from repeated exposure to HIV-1. Some 
preliminary data suggest that peculiar genetic variants can also determine 
an optimal response to ART in HIV-infected subjects. Indeed, in a patient 
with 4 "protective" SNPs in APOBEC3H, TLR3, ERAP2 and MX2, enrolled at 
Santa Maria Annunziata Hospital in Florence, viremia declined rapidly and a 
significant recovery in CD4 + T cell count was observed after treatment. A 
similar trend was detected in a patient with 3 “protective” SNPs (APOBEC3H, 
ERAP2 and MX2) (data not shown). We must consider that since HIV-
infected subjects contracted the infection, despite the presence of these 
protective haplotypes, the "immunological advantage" alone is not sufficient 
to confer a complete shield from HIV-1 infection. However, one or more 
haplotypes, considered to be "protective", could allow for  a better control of 
disease progression if compared with a “susceptible" ones. Given these 
interesting findings, the first aim of this study was to determine whether there 
was a correlation between response to ART and the immune genetic profile 
of HIV-1-infected patients. The investigation was performed considering 
those immune genes known to be protective in viral infection/replication 
control in order to optimize pharmacological intervention in HIV-1-infected 
subjects. However, the results obtained in HIV-1-infected patients, from the 
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ICONA cohort, undergoing ART therapy did not show any significant 
correlations between the genotypes of TLR3, APOBEC3G and MX2 (single 
or combined) and the progression of HIV-1 infection, evaluated in terms of 
viral load and CD4+ or CD8+ T cell count. The only exception is represented 
by ERAP2 gene: in HIV-1-infected patients with a GG homozygosis 
conditions for SNP rs2549782 (Hap A), a significant reduction in viral load 
and a recovery in CD4+ T cells were observed compared to heterozygous or 
homozygous TT patients (Hap B). Analyses for CD8+ T cells showed no 
differences in CD8+ T cell count over 1 year-treatment in Hap A patients, 
conversely, Hap B patients showed a therapy related decrease in CD8+ T 
cell count over the year. This could be explained by a no difference in 
change/year in CD8+ T cell count over time in Hap B patients. The data is 
particularly significant taking into consideration the key role that ERAP2 plays 
in the activation of the immune response against viruses. In fact, ERAP2 
enzyme trims the N- terminally extended residues to generate correct length 
peptides, which are subsequently loaded on MHC class I molecules and 
presented on the cell surface. This, in turn, modulates the antigen repertoire 
available for CD8+ T cell clone stimulation. Therefore, as ERAP2 diplotype 
status determines the abundance of the full length protein product of ERAP2, 
it is possible to speculate that peptides generated by homozygous Hap A 
subjects are “better” in terms of immunogenicity or quantity. The absence of 
correlations between the presence of a “supergenotype” and the progression 
of the disease is unexpected but plausible. First, the allelic variants 
considered to be "resistance genes" have only recently been correlated with 
susceptibility to HIV-1-infection in HESN subjects. Hence, we are not able to 
foresee if  the same variants are able to control/block viral replication in HIV-
infected patients, even if present in combination. In addition, the allelic 
variant associated with the TLR3 gene is related to an increase in receptor 
responsiveness to specific stimuli in in vitro infection assay, resulting in pro-
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inflammatory cytokine production (IL-6, IL-1b, CCL3). This state of hyper-
responsiveness has been linked to a reduced susceptibility to infection by 
many authors [251-253] and may therefore have a protective significance 
during exposure to the virus. However, it is commonly accepted that in HIV-
infected patients the presence of a state of immune activation condition is 
correlated with an increased disease progression [254]. It is therefore likely 
that the same allelic variant plays a diametrically opposite role according to 
the phase of the considered viral cycle. Finally, these first results 
demonstrate that it is not possible to associate the existence of a "super 
genotype" (characterized by the presence of several “protective” allele 
variants) to the control of the infection progression or to a better ART therapy 
response. Nevertheless, positive data obtained in relation to the presence of 
GG genotype for ERAP2 (Hap A), support the necessity to deepen the role 
of this allelic variant in a case/control study, both in the progression of the 
infection and in response to various therapeutic treatments. 
 
Another aim of this PhD project was to further the understanding into the 
mechanism of action of ERAP2 haplotypes in HIV-1 infection susceptibility. 
We performed an in vitro HIV-1 infection assay in PBMCs with different 
ERAP2 diplotype, analyzing ERAP2 role in two different experimental 
conditions: 1) by using an ERAP2 inhibitor; and 2) by adding a recombinant 
(rh) ERAP2 protein in cell cultures. As expected from published data, 
homozygous (Homo) Hap A subjects under HIV-1 infection, presented lower 
viral replication compared to homozygosis Homo Hap B ones in both 
experiments. Moreover, inhibition data showed a dose dependent increase 
of infection, evaluated by p24 levels, in both the haplotypes. This result 
seems to confirm a direct involvement of ERAP2 in resistance of HIV-1 
infection. Remarkably, as increased viral replication was observed also in 
homo Hap B PBMCs treated with  the inhibitor peptide we speculate that a 
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basal expression of ERAP2 FL protein is present even in Hap B subjects 
and/or that ERAP2-AS (Hap B) mRNA undergoes a non-sense-mediated 
decay (NMD) only partially [120]. Anyway, our data are in line with previous 
observations suggesting that high dose of gentamicin antibiotic, a natural 
inhibitor of NMD, do not affect the ERAP2-AS mRNA expression [250]. 
Further analyses are needed to ascertain if ERAP2-AS is expressed even at 
low doses in Homo Hap B subjects and which is its possible role in antigen 
presentation.  Nevertheless data obtained herein confirm the presence of a 
correlation between ERAP2 expression modulation and antigen 
presentation. Indeed, following ERAP2 inhibition, we observed a massive 
increase in ERAP1 aminopeptidase and transporter TAP1 expression, 
suggesting the presence of compensation mechanisms in antigen 
presentation pathway. In addition, increased basal HLAABC (MHC class I) 
expression observed in Homo Hap A subjects, confirms the role of ERAP2 
variants in antigen processing and presentation pathways. In the next future 
it will be extremely interesting to verify if such increase is associated with 
specific HLA class I variants besides HLA B27, whose interplay with ERAP2 
has already been at least partially dissected [98].   
 
The final aim of the project was to investigate and clarify the different 
modulation of peptide production mediated by the two ERAP2 haplotypes 
and the subsequent impact on T cell activation. Therefore, we investigated 
the different trimming phenotypes in DNA model constructs for the two 
haplotypes (Hap A and Hap B) in order to describe a molecular mechanism 
responsible for what observed in HIV-1 infection susceptibility phenotype. 
Results have shown a reduction in trimming function in Hap B models 
compared to the normal Hap A trimming activity. Notably, this latter effect 
results in a reduction of CD8+ T cell response observed in Hap B. These 
data are relevant because can explain a better ability in antigen presentation 
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related to Hap A, compared to Hap B subjects, and this could explicate the 
reduced susceptibility reported in in vitro HIV-1-infection on subjects carrying 
different haplotypes. It should be noted that we did not observe zero 
reduction in trimming function and in cleavage activity in Hap B models and, 
notably, it is coherent with what we observed from protein analyses. Indeed, 
a very low detectable FL ERAP 2 protein also in Hap B samples has been 
detected. This observation could explain the very low trim rate obtained in 
our Hap B models and again, it could be explained by the assumption that 
ERAP2-AS (Hap B) mRNA undergoes a non-sense-mediated decay (NMD) 
only partially [120]. 
Our cleavage data are in line with other observations that have demonstrated 
that ERAP2 SNP rs2549782 is not a loss-of-function variant, but rather a 
“change-in-function” variant that leads to substrate-specific changes in 
enzymatic activity, essentially allowing the enzyme to alter its specificity 
profile for peptide substrates [255]. On the final note, further analyses are 
rquired to investigate the different trimming phenotypes and the resulting 
peptide extracts by using specific techniques, such as reverse-phase HPLC, 
in order to finally assess the different quality and/or quantity of peptide 
extracts derived from ERAP2 haplotypes.  
 
Evidence that ERAP1 and ERAP2 regulates precursor peptide proteolysis in 
the ER is unquestionable. However, recently, the possibility of an alternative 
subcellular localization of the two aminopeptidases has been widely 
discussed [136; 214]. Indeed, a cytosolic and extracellular ERAP1 
localisation has been described by several studies and, even more recently, 
data demonstrating an extracellular ERAP2 localisation in cancer cell 
secretome were reported by Wu et al., [212-214]. For these reasons, we 
decided to investigate if once released in the extracellular milieu ERAP2 still 
maintains its antiviral function. Notably, recombinant ERAP2 addition to in 
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vitro HIV-1-infected PBMCs, without affecting cell viability, resulted in a 
reduction of viral replication in cells isolated by both Hap A and Hap B. This 
protective effect is independent from an increase of HLA-ABC expression 
and/or of perforin and granzyme expression by CD8+ T lymphocytes. We, 
therefore, might speculate that this defensive feature is mediated through an 
unconventional mechanism, distinct from immune system modulation. 
However, further investigations are needed to clarify the “physiological” role 
of ERAP2 in the extracellular milieu as well as the molecular pathway leading 
to this unusual ERAP2 localization. Similarly to ERAP1, once secreted by 
antigen presenting cells, ERAP2 could interact and regulate different and 
unpredictable targets thus regulating mechanisms far away from the one 
exerted in the ER.   
 
To summarise, ERAP2 diplotype status is associated with 
resistance/progression to HIV-1 infection; this phenotype is due to a 
secondary effect on the control in antigen processing/presenting machinery, 
resulting in quantitative and possibly qualitative changes in MHC class I 
complexes on target cells and in a CD8+ T cell immune response modulation. 
This anti-HIV-1 function is preserved even following ERAP2 secretion in the 
extracellular environment. Further analyses are needed to ascertain the 
ERAP2 antiviral involvement in natural resistance to and progression of HIV-
1 infection. These results, nevertheless, suggest a possible basis for 
therapeutic interventions to control of HIV-1 infection. 
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